

REVIEW

P/Q-type calcium channel modulators

V Nimmrich and G Gross

Neuroscience Research, GPRD, Abbott, Ludwigshafen, Germany

Correspondence

V Nimmrich, Neuroscience Research, GPRD, Abbott, Ludwigshafen 67061, Germany.
E-mail: volker.nimmrich@abbott.com

Keywords

ion channels; calcium channels; peptide toxins; calcium antagonists; drug discovery; high-throughput screen

Received

28 February 2012

Revised

15 May 2012

Accepted

28 May 2012

P/Q-type calcium channels are high-voltage-gated calcium channels contributing to vesicle release at synaptic terminals. A number of neurological diseases have been attributed to malfunctioning of P/Q channels, including ataxia, migraine and Alzheimer's disease. To date, only two specific P/Q-type blockers are known: both are peptides deriving from the spider venom of *Agelenopsis aperta*, ω -agatoxins. Other peptidic calcium channel blockers with activity at P/Q channels are available, albeit with less selectivity. A number of low molecular weight compounds modulate P/Q-type currents with different characteristics, and some exhibit a peculiar bidirectional pattern of modulation. Interestingly, there are a number of therapeutics in clinical use, which also show P/Q channel activity. Because selectivity as well as the exact mode of action is different between all P/Q-type channel modulators, the interpretation of clinical and experimental data is complicated and needs a comprehensive understanding of their target profile. The situation is further complicated by the fact that information on potency varies vastly in the literature, which may be the result of different experimental systems, conditions or the splice variants of the P/Q channel. This review attempts to provide a comprehensive overview of the compounds available that affect the P/Q-type channel and should help with the interpretation of results of *in vitro* experiments and animal models. It also aims to explain some clinical observations by implementing current knowledge about P/Q channel modulation of therapeutically used non-selective drugs. Chances and challenges of the development of P/Q channel-selective molecules are discussed.

Abbreviations

A β , amyloid- β ; AD, Alzheimer's disease; CDK, cycline-dependent kinase; LMW, low molecular weight; VGCC, voltage-gated calcium channel

Introduction

The P/Q-type calcium channel (also referred to as Ca_v2.1) is a presynaptic high-voltage-gated calcium channel, which couples neuronal excitation to secretion of neurotransmitter (Ishikawa *et al.*, 2005). The ion-conducting pore is formed by four domains of the α_{1A} subunit, whereas accessory subunits (β , $\alpha_{2\delta}$) modulate channel kinetics and the level of expression. P-type currents were first identified in Purkinje neurons of the cerebellum (Llinás *et al.*, 1989) and are distinguished from Q-type currents identified in cerebellar granule neurons (Randall and Tsien, 1995). Both are characterized by their sensitivity to the venom of *Agelenopsis aperta*, ω -agatoxin IVA (Mintz *et al.*, 1992a), and are generated by ion channels encoded by the CACNA1A gene. A number of splice variants

may explain different phenotypic characteristics of P- and Q-type channels (Bourinet *et al.*, 1999). For convenience and because distinction between these channel subtypes is not always clear, we refer throughout this review to P/Q-type channels. Expression of P/Q-type channels often overlaps with its close analogue, the N-type calcium channel. Yet, the P/Q-type channel is preferably expressed in neurons of the CNS (Bourinet *et al.*, 1999), making it an interesting target for therapeutics addressing neurological disorders.

A number of conditions have been related to P/Q-type channels, some linked by human mutations occurring in familiar inherited diseases (Kisilevsky and Zamponi, 2008). Familiar hemiplegic migraine is an example of a disorder with altered P/Q-type activity. Here, different mutations in the CACNA1A gene lead to altered calcium influx, possibly




Figure 1

Topology of the P/Q-type channel with potential binding sites of channel modulators. ω -Agatoxin IVA and kurtotoxin bind to the outer mouth of the pore forming subunit (linker of the S3–S4 domain), ω -agatoxin IIIA probably to a pore site. ω -Conotoxins bind to the pore region. Pregabalin and gabapentin have been suggested to interact with the $\alpha_2\delta$ subunit. Isoprenaline probably enhances P/Q currents via second messenger cascades.

causing cortical spreading depression, which is thought to underlie migraine aura (Plomp *et al.*, 2001; van den Maagdenberg *et al.*, 2004). In contrast, decreased P/Q channel activity may lead to absence epilepsy and ataxia (Ophoff *et al.*, 1998). It has recently been shown that amyloid- β (A β) oligomers directly increase the recombinant P/Q-type calcium current, and it has been suggested that such modulation can lead to excitotoxic neurodegeneration in Alzheimer's disease (AD; Mezler *et al.*, 2012a). For most of these conditions, there are few or no medications on the market.

In spite of this high, unmet medical need, no specific low molecular weight blockers are known with scaffolds that could serve as structures for lead optimization. This might be due to the fact that the P/Q-type channel is highly homologous to the N-type channel, and that high-throughput assay technology may not successfully deliver specific compounds for lead optimization. Furthermore, development of P/Q-type blockers may be hampered by the fact that peptide tool compounds do not pass the blood–brain barrier, thus do not allow appropriate proof-of-concept studies in animals.

A closer look at the available compound collection may open avenues for drug development, especially when compounds with different biophysical properties are examined for P/Q modulation and may provide clues for a structure–activity relationship. Some proof-of-concept may also come through the interpretation of clinical studies with less specific calcium channel blockers, when taking into account their P/Q-channel activity.

Currently available compounds that carry P/Q-type channel activity can be divided in several groups: (i) Peptidic ion channel blockers deriving from venom of different invertebrate animal species. This group is also host to a subgroup of compounds with two peptides of high selectivity for the P/Q-type channel: the ω -agatoxins. (ii) Low molecular weight compounds that show some efficacy for the P/Q-type channel, but which are not used as therapeutics. (iii) Therapeutics that also affect the P/Q-type channel. Some of those are traditionally named 'calcium antagonists' and thought to target the L-type calcium channel. It also comprises some

anti-epileptics with P/Q channel activity as well as volatile anaesthetics.

P/Q channels as drug target

Voltage-gated calcium channels (VGCC) are protein complexes that mediate calcium influx in response to membrane depolarization. High threshold VGCC (L-type, P/Q-type, N-type and R-type) are activated by strong depolarization, whereas low threshold calcium channels (T-type) open in response to mild depolarization steps. The topology of the P/Q-type channel is illustrated in Figure 1 (for review, see Pietrobon, 2002). The characteristic of the P/Q-type channel is mainly determined by the α_{1A} subunit, which contains the conducting channel and the voltage sensor. The auxiliary subunits β and $\alpha_2\delta$ (and sometimes the γ -subunit) occur in most VGCC and influence trafficking or have a regulatory function (Dolphin, 2009). The pore consists of four homologous domains (I–IV), each of which is composed of six transmembrane segments (S1–S6). S4 is thought to be the voltage sensor. The P/Q-type calcium channel is located at axon terminals as well as somatodendritic compartments of central and peripheral neurons, with some preference for the CNS. At presynaptic sites, opening of the channel mediates synaptic vesicle release via an increase in the local calcium concentration. The pore forming subunit of the P/Q-type calcium channel is encoded by the CACNA1A gene, and multiple splice variants exist that are differentially distributed in the CNS.

Several neurological disorders are caused by mutations in the CACNA1A gene (for review, see Pietrobon, 2010; Rajakulendran *et al.*, 2012). Familiar hemiplegic migraine 1 (FHM1) is a rare, but severe autosomal-dominant subtype of migraine with aura characterized by typical migraine symptoms like unilateral headaches and nausea, but also presents other neurological symptoms such as motor weakness and hemiparesis. Nearly all mutations described in the literature lead to amino acid changes in the α_{1A} subunit, causing a gain-of-function of

the P/Q-type calcium channel. A knock-in mouse carrying a FHM1 mutation showed an increased P/Q-type current and a higher susceptibility to cortical spreading depression (van den Maagdenberg *et al.*, 2004; Tottene *et al.*, 2009). The latter is thought to be the pathophysiological correlate of migraine aura. These studies suggest that cortical hyperexcitability may be an underlying cause for the vulnerability of migraine. A key role of cortical spreading depression in migraine pathogenesis has also been derived from human imaging studies (Hadjikhani *et al.*, 2001). Drugs inhibiting cortical spreading depression may thus be candidates for the prophylaxis of migraine. P/Q channel blockade in the CNS will lower neurotransmission and can thus decrease cortical excitability. Several studies have shown that selective P/Q-type channel blockade can prevent spreading depression (Kunkler and Kraig, 2004; Tottene *et al.*, 2011). Taken together, these data encourage the development of P/Q-type channel blockers as a therapeutic strategy for migraine prophylactic treatment.

Mutations in the P/Q-type calcium channel may also lead to a higher susceptibility for epilepsy. Mice with spontaneous mutations in the CACNA1A gene like *tottering* or *learner* show patterns of generalized seizures (Fletcher *et al.*, 1996). Mutations in the P/Q-type channel have also been linked to epilepsy in humans (reviewed by Khosravani and Zamponi, 2006), although a robust causal relationship has not been demonstrated. Several types of ataxia have been linked to P/Q-type channel mutations: In episodic ataxia type 2, an acetazolamide-responsive type of generalized ataxia, two mutations have been identified that cause a shift in the open reading frame and result in a truncated α_{1A} subunit. Spinocerebellar ataxia type 6 is a progressive form of ataxia caused by an expansion of the polyglutamate repeat in the C-terminus of the α_{1A} subunit (Zhuchenko *et al.*, 1997). As some of these mutations lead to gain-of-function and others to a lack-of-function of the P/Q-type channel, a single P/Q channel modulator may not be sufficient to treat all P/Q-related disorders.

The P/Q-type calcium channel has also been suggested to contribute to the pathology of AD. It is now an accepted view that A β oligomers cause cognitive decline by altering synaptic function in patients with AD. Early studies using non-specific A β peptides reported that application of A β to neurons causes an increase in calcium currents (He *et al.*, 2002; Rovira *et al.*, 2002). I.c.v. injection of A β peptides caused disturbance of synaptic plasticity in rats, which was reversed by calcium antagonists (Freir *et al.*, 2003). Several publications then showed that application of A β peptides to neurons increased N and P/Q-type calcium currents (MacManus *et al.*, 2000; Ramsden *et al.*, 2002). We recently tested the effect of A β oligomers on recombinantly expressed P/Q-type calcium currents in *Xenopus* oocytes and showed that the α_{1A} subunit of the channel was specifically modulated, leading to an increased calcium influx. It was speculated that this increase might cause excitotoxicity and lead to synaptic decline in AD (Mezler *et al.*, 2012a). The view that A β protein interacts with presynaptic calcium channels in AD patients was supported by the observation that A β oligomers co-localize with axon terminals in AD brains (Kokubo *et al.*, 2005; Noguchi *et al.*, 2009). It has also been shown that endogenous A β increases the frequency of EPSCs (Abramov *et al.*, 2009), indicating an up-regulation of presynaptic function by amyloid protein.

P/Q-type channels have also been discussed as a drug target for pain (Yakash, 2006; Lewis *et al.*, 2012). Although P/Q-type channels contribute to neurotransmission at nociceptive synapses (Heinke *et al.*, 2004), and efficacy in pain models has been reported (Nebe *et al.*, 1997), N-type channels are likely to be the preferred target for this therapeutic area (for review, see Lewis *et al.*, 2012).

The P/Q-type channel is widely expressed in the CNS. Its general expression in all brain areas – especially in the cerebellum – may be a challenge for drug development, as P/Q blockade in the cerebellum may cause gait and movement disturbances. Indeed, P/Q channel knock-out mice exhibit symptoms of ataxia and dystonia (Jun *et al.*, 1999; Fletcher *et al.*, 2001). Addressing a particular splice variant expressed in the brain region of interest could be a sophisticated approach for drug development to bypass the effects of the cerebellum. Bourinet *et al.* (1999) identified a number of splice variants with different pharmacological properties. A larger group of splice variants was later identified and exemplifies the diversity of P/Q channel variation (Soong *et al.*, 2002). The challenge would be the identification of a compound with sufficient selectivity for a given splice variant. So far, there is no detailed expression map of the various isoforms available that would support a particular splice variant as drug target. Variant α_{1Ab} shows preferential expression in hippocampal areas (Bourinet *et al.*, 1999) and could be an interesting target for development of compounds against AD. Yet, its full pattern of CNS distribution is not known. A second approach, which is increasingly implemented in drug discovery, is the development of state-dependent therapeutics. These molecules are designed to preferably bind to the inactivated state of the channel and thus are thought to target channels at overactive synapses (and thus only under pathological conditions), while sparing normal synapses. A compound with high level of state-dependency may be favourable, particularly for the indications migraine and epilepsy, where the pathophysiology involves prolonged depolarization of the membrane over seconds or minutes. Other conditions like pain may benefit from use-dependent compounds, which do not block the channel at normal firing patterns, but instead bind to the channel during high-frequency firing. In the pharmaceutical development of ion channel blockers it is now state-of-the-art to strive for a high level of state- or use-dependence in order to increase the therapeutic window. We recently described a high-throughput screening assay with a subsequent electrophysiological secondary screening, which was designed to identify state-dependent P/Q-type channel blockers (Mezler *et al.*, 2012b). Whether these approaches will actually reduce the number and intensity of adverse effects in humans has yet to be shown in clinical trials.

In contrast, some compounds bind to the open state of the channel and thereby delay its deactivation. These drugs lead to a facilitation of calcium influx and may be beneficial in certain types of ataxia, where calcium entry through the P/Q channel is diminished.

Here, we have attempted to give an overview on the available compounds with P/Q channel modulating activity. Only two peptide toxins are selective for P/Q-type channels, the majority of the compounds described are non-selective and often more potent for other targets.

Table 1

Reported peptide blockers with P/Q-type channel activity (in alphabetical order)

Compound	P/Q channel activity	Activity on other channels	Reference	Species
Calcicludine	Complete block at 10 nM (native P-type current) to slight block at 100 nM (recombinant P/Q channel)	Block of N and L-type channels at 25–250 nM	Schweitz <i>et al.</i> , 1994; Stotz <i>et al.</i> , 2000	<i>Dendroaspis angusticeps</i>
DW13.3	IC ₅₀ = 4.3 nM	Blocks N-type channels with an IC ₅₀ of 14.4 nM, L-type channels with 26.8 nM and R-type channels 96.4 nM	Sutton <i>et al.</i> , 1998	<i>Filistata hibernalis</i>
Kurtoxin	50% inhibition of initial current amplitude (K_D = 14 nM), but facilitation of steady-state current	Block of N, L and T-type currents (K_D 456, 72 and 49 nM respectively)	Sidach and Mintz, 2002	<i>Parabuthus transvaalicus</i>
Phonetoxin IIA	>70% block at 10 nM	Full block of N-type currents at 3.5 nM, 20% block of R-type currents (17 nM)	Dos Santos <i>et al.</i> , 2002	<i>Phonoetrica nigriventer</i>
PnTx3-6	IC ₅₀ = 263 nM	IC ₅₀ for N-type channel 136 nM, R-type channel 607 nM and L-type channel 122 nM	Vieira <i>et al.</i> , 2005	<i>Phonoetrica nigriventer</i>
SNX482	partial block at 300 nM	R-type complete block at 200 nM (Bourinet <i>et al.</i> , 2001); partial block of Na channels at 500 nM	Arroyo <i>et al.</i> , 2003	<i>Hysteroocrates gigas</i>
ω -agatoxin-IIIa	K_D = 9 pM	N-type, R-type (K_D = 5–9 pM)	Yan and Adams, 2000	<i>Agelenopsis aperta</i>
ω -agatoxin-IVA	IC ₅₀ = 2–1000 nM	–	Mintz <i>et al.</i> , 1992a,b; Sather <i>et al.</i> , 1993; Stea <i>et al.</i> , 1994; Bourinet <i>et al.</i> , 1999; Hans <i>et al.</i> , 1999	<i>Agelenopsis aperta</i>
ω -agatoxin-IVB	K_D = 3 nM, complete block at 800 nM	–	Adams <i>et al.</i> , 1993	<i>Agelenopsis aperta</i>
ω -conotoxin CVIB	IC ₅₀ = 23 nM	Blocks N-type channel with an IC ₅₀ of 23 nM	Motin <i>et al.</i> , 2007	<i>Conus catus</i>
ω -conotoxin MVIIC	IC ₅₀ <0.5 μ M	Blocks N-type channels with an IC ₅₀ of 18 nM	Sather <i>et al.</i> , 1993; McDonough <i>et al.</i> , 1996	<i>Conus magus</i>
ω -Grammtoxin-SIA	complete block at 50 nM	complete block of N-type current at 500 nM, binding to the <i>drkl</i> K ⁺ channel	McDonough <i>et al.</i> , 1997; Takeuchi <i>et al.</i> , 2002	<i>Grammostola spatulata</i>
ω -Lsp-IA	Partial block at 10 nM	– (?)	Pluzhnikov <i>et al.</i> , 2007	<i>Geolycosa sp.</i>
ω -PnTx3-3	79% block at 60 nM	45% block of L-type current at 80 nM	Leão <i>et al.</i> , 2000	<i>Phonoetrica nigriventer</i>

References in column 4 report activities on the P/Q-type channel. Activities on other targets are reported in the same references, unless explicitly stated in column 3. The peptide toxins were originally isolated from venom of the species stated in column 5.

ω -Agatoxins

Spider venoms are a rich source of ion channel blockers. Agatoxins comprise a group of toxins from the American funnel web spider *A. aperta* that target different classes of ion channels (Adams, 2004). Table 1 summarizes the agatoxins with P/Q channel activity. Two toxins out of this venom screen are specific for P-type channels (i.e. ω -agatoxin IVA and ω -agatoxin IVB). Both peptides share the same specificity and affinity for P-type currents, but seem to exhibit different

kinetics (Adams *et al.*, 1993). ω -Agatoxin IVA blocks P-type channels in rat Purkinje neurons with an IC₅₀ of 2–10 nM and only marginally affects other currents (Mintz *et al.*, 1992a,b). ω -Agatoxin IVA blocks Q-type channels less effectively than P-type channels, probably due to different splice variants encoding each subtype (Bourinet *et al.*, 1999). The cloned α_{1A} subunit may reflect the Q-type channel, which would explain the finding that the recombinant α_{1A} is much less sensitive to ω -agatoxin IVA than native P-type currents. Sather *et al.* (1993), for example, revealed that recombinant α_{1A} channels

are 100-fold less sensitive to ω -agatoxin IVA than P-type channels of rat cerebellar Purkinje neurons. Less sensitivity of recombinant α_{1A} channels for ω -agatoxin IVA was also described by other authors (Stea *et al.*, 1994; Bourinet *et al.*, 1999). ω -Agatoxin IVA shifts the activation curve to more positive potentials, indicating that it alters gating of the channel (Winterfield and Swartz, 2000; McDonough *et al.*, 2002). Strong depolarization steps remove the toxin from the channel (Mintz *et al.*, 1992b), indicating that the affinity of the toxin is low for the open state of the channel. In contrast to other calcium channel blockers, ω -agatoxin IVA binds outside of the pore region of the α_{1A} subunit (Winterfield and Swartz, 2000), which may explain its selectivity compared with pore blockers. The ω -agatoxin IVA receptor has been localized to the S3–S4 linker, which is also a binding site for gating modifier molecules on K^+ and Na^+ channels (Rogers *et al.*, 1996; Li-Smerin *et al.*, 2000). It has been suggested that either the hydrophobic C-terminal part of the peptide (Kim *et al.*, 1995) or charged residues in the mid-part region (Adams *et al.*, 1993) mediate activity. ω -Agatoxin-IVB is the second specific blocker of P-type currents in cerebellar Purkinje neurons with a K_D of 3 nM, and no effect on T-type, L-type or N-type calcium channels (Adams *et al.*, 1993). Also, similar to ω -agatoxin IVA, its release from the channel is strongly increased by large depolarizations steps. The only difference between the toxins is the kinetics (block by ω -agatoxin-IVB develops eightfold slower and is also reversed more slowly during washout; Adams *et al.*, 1993). The three-dimensional solution structure of both peptides has been determined by NMR: both are composed of 48 amino acids internally connected by four disulfide bonds (Adams *et al.*, 1993; Kim *et al.*, 1995). In contrast to these specific peptides, ω -agatoxin-IIIA has high affinity to all presynaptic calcium channels (N, P/Q and R) in the low picomolar range (Yan and Adams, 2000). Functionally, it exhibits only a partial block by decreasing single-channel conductance (McDonough *et al.*, 2002). It also blocks L-type channels (Mintz *et al.*, 1991; Ertel *et al.*, 1994).

Other spider toxins

P/Q blockers have been isolated from a number of spider venoms beyond *A. aperta*. ω -Grammotoxin SIA was purified from the venom of the tarantula spider *Grammostola spatulata* (Lampe *et al.*, 1993). It affects both N- and P/Q-type calcium channels (McDonough *et al.*, 1997). Isolated P-type currents in rat cerebellar Purkinje neurons were completely blocked by 50 nM ω -grammotoxin SIA, and this effect seems to be through a modification of channel gating. Resting states are stabilized by the toxin (McDonough *et al.*, 1997). Channel binding has been suggested to occur through a hydrophobic patch of the surface of ω -grammotoxin SIA, but seems not to be restricted to calcium channels (e.g. low affinity binding to K channels; Takeuchi *et al.*, 2002). A peptide homologous to ω -grammotoxin SIA, SNX482, is the 41-amino-acid toxin of the African tarantula *Hysterocrates gigas*, which has been found to block P/Q channels as well as sodium channels (Arroyo *et al.*, 2003), in addition to its earlier demonstrated effect on R-type currents (Bourinet *et al.*, 2001).

ω -PnTx3-3, a peptide derived from the South American 'armed' spider *Phoneutria nigriventer*, inhibits most of the isolated P/Q-type current at 60 nM in cerebellar granule

neurons, but is also effective for N and L-type currents (Leão *et al.*, 2000). A second toxin was isolated from this spider (i.e. phonetoxin IIA) (Cassola *et al.*, 1998). This toxin is large with 76 amino acids and has some similarity to ω -agatoxin-III family. It irreversibly blocks recombinant P/Q- and N-type currents, and partly inhibits R-type currents (Dos Santos *et al.*, 2002). A third toxin from *P. nigriventer*, PnTx3-3, blocks L, P/Q, R and N-type channels (Vieira *et al.*, 2005). P/Q currents recombinantly expressed in cell lines were blocked with an IC_{50} of about 200 nM. A novel 47-amino-acid peptide toxin, ω -Lsp-IA, was recently identified in the venom of a *Geolycosa* sp.; it attenuates activation kinetics at 10 nM in cerebellar Purkinje neurons and has been suggested to be specific for P/Q-type currents (Pluzhnikov *et al.*, 2007).

DW13.3 is a 74-amino-acid toxin derived from *Filistata hibernalis*, which blocks all recombinant α_{1A-E} currents in *Xenopus* oocytes (Sutton *et al.*, 1998), most potently the α_{1A} channel with an IC_{50} of 4.3 nM. It was also observed to block ω -Agatoxin IVA-sensitive currents in cerebellar Purkinje neurons (saturation at 32–100 nM).

At this point, one may raise the question why particularly arachnids rely on P/Q channel block for prey capture and defence. Do insects have ion channels that are particularly sensitive to P/Q-modulating toxins? Many spiders hunt insects and ω -agatoxin IVA-sensitive currents have indeed been shown to occur in various insect species (Benquet *et al.*, 1999). Furthermore, functional P/Q-like currents can even be recorded in species as low as nematodes (*Caenorhabditis elegans*; Mathews *et al.*, 2003). It is possible that spiders rely on P/Q blockade to reach a larger spectrum of invertebrate animals.

ω -Conotoxins

Conotoxins are peptidic toxins derived from venomous marine cone snails. Each of the 500 *Conus* species expresses approximately 100 different conopeptides, so that a pool of more than 50 000 pharmacologically active compounds may exist (Terlau and Olivera, 2004). Most conopeptides target ion channels, some of them with high specificity, and many have been thoroughly used as research tools. ω -Conotoxins target calcium channels and largely derive from fish-hunting cone snails. A derivative of a *Conus magus* peptide ω -conotoxin MVIIA (an N-type specific inhibitor) is now clinically used under the name Prialto® (ziconotide, SNX-111) as a therapeutic for chronic pain. A number of other conopeptides are in clinical development, including an N-type channel blocker (ω -conotoxin CVID) in phase II (Han *et al.*, 2008). Medicinal chemistry efforts have enabled cyclization of conopeptides to improve bioavailability. Hence, conopeptides may in future be usable for oral drug application, opening further avenues for the development of ion channel-selective therapeutics from peptide blockers (Clark *et al.*, 2005).

Table 1 summarizes reported conopeptides with P/Q channel activity. ω -Conotoxin MVIIC, a peptide identified from a cDNA library from the venom gland of *C. magus*, inhibits calcium currents in cerebellar Purkinje cells with an IC_{50} between 1 and 10 μ M (Hillyard *et al.*, 1992) and also inhibits P-type currents in hippocampal CA1 pyramidal neurons (Hillyard *et al.*, 1992). It also targets the N-type channel but does not affect the L-type channel. P-type current block by ω -conotoxin MVIIC is slower than for

N-type channels and also reverses slowly (McDonough *et al.*, 1996). In contrast to agatoxin, ω -conotoxin MVIIC blocks currents generated by the recombinantly expressed α_{1A} subunit in *Xenopus* oocytes more potently than the native current (70% block by 5 μ M; Stea *et al.*, 1994; $IC_{50} < 0.15$ μ M). However, the block is rather slow (Sather *et al.*, 1993). ω -Conotoxin MVIIC binds to P-type calcium channels with an affinity of 0.5 nM (estimated by McDonough *et al.*, 1996), but the specific P/Q channel blocker ω -agatoxin-IVA cannot prevent binding of ω -conotoxin MVIIC (McDonough *et al.*, 1996). The high content of basic amino acids residues in ω -conotoxins seems to mediate inhibition (Nadasdi *et al.*, 1995), while a mutation of the tyrosine residue at position 13 disrupts binding of the toxin and may be part of the toxin pharmacophore (Nielsen *et al.*, 1999a). In line with its inhibitory properties on presynaptic calcium channels, ω -conotoxin MVIIC completely prevents synaptic transmission of hippocampal CA3 neurons (Wu and Saggau, 1995).

Another ω -conotoxin exhibiting P/Q channel activity is ω -conotoxin CVIB. It reversibly inhibits both N and P/Q-type calcium channels expressed in *Xenopus laevis* oocytes with an IC_{50} of about 23 nM. The R-type current is not affected at 200–500 nM. In dorsal root ganglion cells it blocks isolated P/Q-type as well as N-type currents at 100 nM (Motin *et al.*, 2007). This P/Q-type block (but not the N-type block) is irreversible in these cells.

Other peptide toxins

Table 1 gives an overview of peptides with reported P/Q channel activity. Calcicludine, a 60 amino-acid peptide toxin isolated from the venom of the green mamba *Dendroaspis angusticeps*, blocks L-type currents recombinantly expressed in HEK293 cells but also exhibits some voltage-dependent block of P/Q- and N-type currents at 100 nM (Stotz *et al.*, 2000). In rat cerebellar Purkinje neurons, it blocks P-type currents more potently with an IC_{50} of 1–5 nM (Schweitz *et al.*, 1994), with a lower IC_{50} for L- and N-type channel block (10–100 nM). The peptide binds to olfactory bulb membranes with a K_D of 15–36 pM. Kurtosin, derived from the scorpion venom *Parabuthus*, is interesting because it reduces high threshold calcium currents in thalamic neurons but enhances P-type currents in Purkinje cells (Sidach and Mintz, 2002).

Low molecular weight calcium channel blockers

In drug development, low molecular weight blockers are usually preferred, as they exhibit several advantages over peptide blockers: First of all, compounds can be selected for tissue penetration, distribution and pharmacokinetics. Peptides usually have extremely low penetration of tissue barriers, which is especially important for CNS indications where the blood–brain barrier often prevents accessibility of the target. Thus, small molecules have a higher potential for improvement of structure–activity relationship. Unfortunately, there is no small molecule known, which is specific to P/Q-type channels. Table 2 provides an overview of the low molecular weight compounds with reported activities for P/Q-type channels. Probably the best-examined small molecule P/Q channel modulator is the cycline-dependent kinase (CDK) inhibitor roscovitine (seliciclib). Roscovitine has been

tested for clinical efficacy in a phase II cancer trial (Aldoss *et al.*, 2009). Yan *et al.* (2002) showed that roscovitine enhanced P/Q-type calcium tail currents with an IC_{50} of about 20 μ M in isolated neostriatal interneurons. This effect was the result of slowed deactivation kinetics. P/Q channel modulation was independent of CDK inhibition. Consequently, roscovitine enhances presynaptic vesicle release in cultured neurons. A subsequent study elaborated on the kinetics of this modulation and found that roscovitine slows deactivation of all recombinantly expressed presynaptic calcium channels (P/Q, N and R) in stably transfected cell lines (Buraei *et al.*, 2006), albeit at high concentrations (EC_{50} for P/Q: 120 μ M). Recently, Buraei and Elmslie (2008) showed that R-roscovitine exhibits both agonist and antagonist effects on all presynaptic calcium channels. Agonist properties were observed at a lower concentration (28 μ M) than the antagonistic effect (130 μ M). The agonism is specific for the stereoisomer and less pronounced for S-roscovitine and is determined by the residue on the C2 position of the molecule. The antagonism by R-roscovitine was state-dependent, with higher potency at depolarized potentials. Such bidirectional regulation has also been described for two anti-epileptic drugs (benidipine and cilnidipine). Interestingly, a bidirectional modulation of ion channels is brought about by a number of conditions, such as changes in the holding potential (Kass, 1987). It is also not restricted to low molecular weight compounds (Koch *et al.*, 2004; Mezler *et al.*, 2012a) and may simply be observed by changing the expression system (Mezler *et al.*, 2012a). Cho and Meriney (2006) reported a 427% attenuation of the deactivation kinetics of calcium currents by roscovitine in *Xenopus* motorneurons and consequently increased transmitter release. Apparently, the enhancement of the tail current in such a system predominates, perhaps as the tail current comprises most of the total current during the brief time of an action potential. Such enhanced presynaptic function by roscovitine may cause excitotoxicity, as shown in cultured neurons (Monaco and Vallano, 2005).

A second compound causing current enhancement of P/Q-type calcium currents is the β -adrenoceptor agonist isoprenaline. The effect on P/Q is mediated by a cAMP cascade (Huang *et al.*, 1996). It causes an increase in the excitatory postsynaptic potential in rat amygdale slices, which can be blocked by ω -agatoxin IVA (Huang *et al.*, 1996). A direct enhancement of ω -agatoxin-sensitive calcium currents by 15 μ M isoprenaline was subsequently shown (Huang *et al.*, 1998).

Interestingly, a number of NMDA receptor antagonists have P/Q channel activity: Eliprodil has been reported to block P-type currents in cerebellar Purkinje neurons (Biton *et al.*, 1995). The IC_{50} for P-type channel block was 1.94 μ M, which is in the range of the IC_{50} for N and L-type channels. The block was not state-dependent. The NMDA receptor antagonist antazoline reversibly blocks P/Q-type channels with an IC_{50} of 10 μ M. This block was state-dependent (Milhaud *et al.*, 2002). It has been suggested that such block may contribute to the neuroprotective properties of imidazoles. In this respect, it should be mentioned that the clinically used NMDA receptor blocker memantine also inhibits P/Q-type/N-type currents (Lu *et al.*, 2010). It is assumed that the therapeutic effect of memantine is mediated by a partial

Table 2

Reported LMW blockers with P/Q-type channel activity (in alphabetical order)

Compound	P/Q channel activity	Activity on other targets	Reference
A-1048400	IC ₅₀ = 1.3 µM (inactivated state), 16 µM (hyperpolarized state)	N-type: IC ₅₀ = 0.8–4.1 µM; T-type channel: IC ₅₀ = 0.9–2.6 µM	Scott <i>et al.</i> , 2012
Amlodipine	IC ₅₀ = 3–11.5 µM	L-type channel (IC ₅₀ = 1.2–4.2 µM); N-type (IC ₅₀ = 0.14–7.9 µM)	Furukawa <i>et al.</i> , 1999
Antazoline	IC ₅₀ = 10 µM	Antagonizes NMDA receptors (IC ₅₀ 4 µM; Milhaud <i>et al.</i> , 2002)	Milhaud <i>et al.</i> , 2002
Barnidipine	IC ₅₀ = 13.1–213 µM	L-type channel (IC ₅₀ = 1.2–3.1 µM); N-type (IC ₅₀ = 7.1–1370 µM)	Furukawa <i>et al.</i> , 1999
Cilnidipine	IC ₅₀ = 20.8–58.5 µM	L-type channel (IC ₅₀ = 5.3–12.7 µM); N-type (IC ₅₀ = 4.2–39.4 µM)	Furukawa <i>et al.</i> , 1999
Diltiazem	IC ₅₀ = 97 µM; IC ₅₀ = 169 µM;	L-type channel (IC ₅₀ = 33.3 µM–40 µM; Diochot <i>et al.</i> , 1995; Hockerman <i>et al.</i> , 2000)	Ishibashi <i>et al.</i> , 1995; Hockerman <i>et al.</i> , 2000
Dodecylamine	IC ₅₀ = 2.1 nM	Blocks L-type channels with an IC ₅₀ of 100 nM, N-type channels 1.8 µM, R-type channels 2.0 µM	Beedle and Zamponi, 2000
Eliprodil	IC ₅₀ = 1.9 µM	Antagonizes NMDA receptors with an IC ₅₀ of 670 nM and N and L-type currents with an IC ₅₀ of 1.48 µM (Biton <i>et al.</i> , 1994)	Biton <i>et al.</i> , 1995
Flunarizine	IC ₅₀ = 1.77–11 µM	hERG (IC ₅₀ = 5.7 nM) Na channels (use-dependent block at 100 nM; Trepakova <i>et al.</i> , 2006), T-type (IC ₅₀ = 0.1–19); L-type channels (IC ₅₀ = 0.1–11 µM), N-type channel 0.8 µM	Geer <i>et al.</i> , 1993; Ye <i>et al.</i> , 2011
Fluspirilene	IC ₅₀ = 6 µM	Nanomolar affinity for D2 receptors (Schotte <i>et al.</i> , 1996); N-type: 2 µM; 90% block of T-type current at 1 µM (Enyeart <i>et al.</i> , 1992)	Sah and Bean, 1994
Gabapentin	IC ₅₀ = 98 µM; reduces P/Q-type mediate effect on EPSCs at 20 µM; binds to the α2δ subunit; chronic application modulates P/Q-type inactivation kinetics >0.3 µM; attenuates P/Q-mediated noradrenalin release	L-type (partial block at 100 µM); reduces N-type mediate effect on epscs at 20 µM	Dooley <i>et al.</i> , 2002; Fink <i>et al.</i> , 2002; Kang <i>et al.</i> , 2002; Sutton <i>et al.</i> , 2002; Oka <i>et al.</i> , 2003a,b; Cunningham <i>et al.</i> , 2004
Halothane	Partial block at 0.59 mM	Na channels (IC ₅₀ = 0.75 mM; Rehberg <i>et al.</i> , 1996); enhancement of GABA _A receptor-mediated chloride currents (Jones <i>et al.</i> , 1992); N-type, R-type, L-type: Partial block at 0.59 mM	Kamatchi <i>et al.</i> , 1999; Kameyama <i>et al.</i> , 1999
Isoflurane	Partial block at 0.7 mM	Na channels (IC ₅₀ = 0.85 mM; Rehberg <i>et al.</i> , 1996); enhancement of GABA _A receptor-mediated chloride currents (Jones <i>et al.</i> , 1992); N-type, R-type, L-type: Partial block at 0.7 mM	Kamatchi <i>et al.</i> , 1999
Isoproterenol	Enhancement of P/Q currents at 15 µM	β-adrenoreceptor ($K_d = 1.7 \times 10^{-7}$; Brown <i>et al.</i> , 1976)	Huang <i>et al.</i> , 1996; 1998
Lamotrigine	Partial block at 30 µM	Partial block of N-type channels at 30 µM; partial blockade of sodium channels at 1 µM (Stefani <i>et al.</i> , 1997)	Stefani <i>et al.</i> , 1996a
Levetiracetam	Partial block at 100 µM	Partial block of N-type at 100 µM; binds to SV2A (Lynch <i>et al.</i> , 2004)	Pisani <i>et al.</i> , 2004

Table 2

Continued

Compound	P/Q channel activity	Activity on other targets	Reference
LY393615	IC ₅₀ = 4 µM	N-type (IC ₅₀ = 1.9 µM); R-type (IC ₅₀ = 5.2 µM)	O'Neill <i>et al.</i> , 2001
Memantine	100 µM memantine abolishes P/Q-type channel mediated glutamate release	Blocks NMDA receptor currents (IC ₅₀ = 0.47–0.93 µM; Bresink <i>et al.</i> , 1996); 100 µM memantine abolishes N-type channel mediated glutamate release	Lu <i>et al.</i> , 2010
Neuromed 2	IC ₅₀ = 4.5 µM	N-type (IC ₅₀ 0.12–0.16 µM); T-type (81 nM); L-type (IC ₅₀ 133 µM)	Yamamoto and Takahara, 2009
Neuromed 5	IC ₅₀ = 1.659 µM	N-type (13–60 nM); T-type (0.27–0.579 µM); L-type (144 µM)	Yamamoto and Takahara, 2009
Nicardipine	IC ₅₀ = 21.1–85 µM	L-type (IC ₅₀ = 9.6–24 µM); N-type (IC ₅₀ = 59.9 µM–7.6 mM)	Furukawa <i>et al.</i> , 1999
Nimodipine	IC ₅₀ = 200–500 nM (little activity on P/Q detected by Furukawa <i>et al.</i> , 1999)	L-type channel (IC ₅₀ = 1 µM);	Diochot <i>et al.</i> , 1995; Mansvelter <i>et al.</i> , 1996
NMED-160 (Neuromed 1)	IC ₅₀ = 0.12–0.65 µM	N-type (IC ₅₀ = 0.04–0.2 µM); L-type (IC ₅₀ = 0.3–0.5 µM)	Yamamoto and Takahara, 2009
R-roscovitine	Decreases step current and enhances tail currents (EC ₅₀ = 120 µM)	Decreases step current and enhances tail currents of N-type and R-type calcium channels with EC ₅₀ of 54 µM; inhibits L-type current, K-currents and Na currents without tail enhancement; Inhibitor of cdc2, cdk2, cdk2 and cdk5 (IC ₅₀ = 0.2–0.7 µM; Meijer <i>et al.</i> , 1997)	Buraei <i>et al.</i> , 2006; Buraei and Elmslie, 2008
TROX-1	IC ₅₀ = 0.4 µM	N and R-type channels (IC ₅₀ = 0.4 µM)	Abbadie <i>et al.</i> , 2010
Verapamil	Full block at 50 µM; IC ₅₀ = 62 µM	L-type channel (IC ₅₀ = 4 µM); N-type channel (full block at 40 µM)	Diochot <i>et al.</i> , 1995; Ishibashi <i>et al.</i> , 1995; Dobrev <i>et al.</i> , 1999
α-Eudesmol	IC ₅₀ = 3.6 µM	N-type current: IC ₅₀ = 6.6 µM;	Asakura <i>et al.</i> , 1999; Horak <i>et al.</i> , 2009

References in column 4 report activities on the P/Q-type channel. Activities on other targets are reported in the same references, unless explicitly stated in column 3.

block of NMDA-receptor currents, thereby inhibiting excitotoxicity (Rogawski and Wenk, 2003). One may speculate that a presynaptic calcium channel block could contribute to a common silencing of overactive synapses. In this respect, a state-dependent block of presynaptic calcium channels may leave normal transmission unaltered, while buffering tonic glutamatergic transmission.

Dodecylamine is another low molecular weight blocker with activity for P/Q. It inhibits recombinantly-expressed P/Q-type currents with an IC₅₀ of 2.1 µM, but it is not specific (Beedle and Zamponi, 2000). The block is use-dependent and restricted to the open state.

It should be mentioned that ethanol, although at very high concentrations, inhibits P/Q-type currents (Solem *et al.*, 1997). Although the principal pharmacological effect of ethanol is likely to be on other systems in the CNS, it would be worth examining whether alcohol-induced ataxia could be a result of P/Q channel blockade. The possibility that ataxia is caused by P/Q-channel loss-of-function in several genetic models has been well described in the literature.

Calcium channel blockers in development

The development of calcium channel blockers, particularly of the N-type, has been recently inspired by the FDA approval of the peptidic calcium channel blocker ziconotide (Piralt®). This peptide is a synthetic form of ω-conotoxin MVIIA derived from *C. magus* and blocks N-type calcium channels on nociceptive A-δ and C nerve fibre endings in lamina I and II of the spinal cord dorsal horn. Ziconotide is efficacious in opioid-resistant pain as well as other severe pain states (Pexton *et al.*, 2011). There does not seem to be development of tolerance (Webster *et al.*, 2009), underlining its advantage over opioids especially for non-cancer patients. However, there are multiple issues regarding adverse effects and the route of administration: First of all, ziconotide is a water-soluble and polar molecule with high molecular weight and thus has limited tissue penetration. Systemic administration inhibits noradrenaline release at sympathetic neurons and therefore exhibits systemic adverse effects like blood pressure changes. It has little effect on parasympa-

thetic nerves (Wermeling, 2005). Thus, intrathecal administration is mandatory. Yet, even with this application route, there are common central side effects like memory impairment, dizziness or speech disorders, leading to dropout rates of up to 39% in clinical studies (Ellis *et al.*, 2008; Webster *et al.*, 2009). Recently, a number of companies tried to overcome these hurdles by the development of state-dependent, low molecular weight compounds with improved pharmacokinetic and side effect profiles. Small molecules would be accessible to chemical optimization processes for improving structure–property relationships (SPR), facilitating oral availability and tissue distribution. A recent trend is the development of state-dependent channel blockers that are designed to only inhibit voltage-gated ion channels at inactivated state. It is thought that these molecules prevent excessive neurotransmission of cells under pain conditions, while leaving normal synaptic function unaltered. Thus, there is the hope for small molecule calcium channel blockers that can be applied systemically with a low side effect profile. These improvements, however, were accompanied by lack of selectivity, especially against the P/Q-type channel (Yamamoto and Takahara, 2009). As a result, most small molecule ‘N-type channel blockers’ in pharmaceutical development are mixed N-P/Q-type blockers (see Table 2 for an overview). Neuromed Pharmaceuticals recently disclosed their compound NMED-160, which blocks N-type and P/Q-type channels in the low nanomolar range. NMED-160 is the only small molecule molecular weight blocker in clinical trials [Neuromed, Merck give up on new pain drug. *Philadelphia Business Journal*. August 2007. Available from: <http://www.wizjournals.com/philadelphia/stories/2007/08/06/daily17.html> (Last access April 2011)]. Channel block by NMED-160 seems to be use-dependent (McNaughton *et al.*, 2008), which should provide an advantage over non-state-dependent peptides. A number of compounds have been developed fairly recently, some of which have been shown to affect P/Q-type channels (Neuromed 2–7; reviewed by Yamamoto and Takahara, 2009). Merck developed a substituted N-triazole oxindole (TROX-1), which is orally available and showed efficacy in a number of pain models (Abbadie *et al.*, 2010). TROX-1 is potent and state-dependent (IC_{50} = 400 nM). However, in dorsal root ganglion cells, it blocks all Ca_v2 channels, including the P/Q-type channel, and it also inhibits recombinantly expressed P/Q channels with a potency similar to that for the N-type channel. Elli Lilly published an N-type blocker (LY393615) with an IC_{50} for N-type channels of 1.9 μ M (recombinantly expressed in HEK293 cells), which blocks P/Q channels with similar potency (IC_{50} for P/Q: 4 μ M in isolated Purkinje cells; O’Neill *et al.*, 2001). Abbott Laboratories recently published a state-dependent, orally available calcium channel blocker, which does not affect the L-type calcium channel (A-1048400; Scott *et al.*, 2012). The IC_{50} for the P/Q-type channel is 16.3 μ M at a hyperpolarized state and 1.3 μ M at an inactivated state. This compound also potently blocks N-type, R-type and T-type channels (IC_{50} at inactivated state: 0.8, 0.9 and 1.6 μ M respectively). Current drug discovery efforts focusing on the discovery of P/Q-type channel blockers for CNS disorders may provide us with more selective, small molecule blockers for P/Q-type channels (Mezler *et al.*, 2012b).

Clinically used therapeutics that block calcium channels

A number of therapeutics modulate P/Q channels, although the therapeutic effect is thought to be mediated by other targets. A precise understanding of the respective target profile is often missing and may be valuable for the development of more selective compounds with fewer adverse effects. Table 3 gives an overview of clinically used compounds with P/Q-type channel activity.

Calcium antagonists. In 1964, Albrecht Fleckenstein showed that verapamil mimics the effect of Ca^{2+} removal on electrically-stimulated guinea pig papillary muscle (Fleckenstein-Grün, 1994). He created the name ‘calcium antagonists’ to separate the principle as an alternative to β -receptor blockade and confirmed the idea of calcium channel blockade by voltage-clamp analysis. Shortly afterwards, Bayer AG developed a highly potent calcium channel blocker, Bay a 1040, which was later named nifedipine. In the following years, a large number of calcium antagonists with distinct properties were identified by the pharmaceutical industry, belonging to different classes: benzothiazepines and phenylalkylamines. Some, like verapamil, have inotropic, chronotropic and dromotropic effects besides their vasodilator properties, whereas nifedipine was largely a vasodilator. Calcium antagonists are used clinically for the treatment of hypertension, coronary heart disease and cardiac arrhythmia. Their principal mode of action is the inhibition of L-type calcium channels in smooth muscle cells (including those of coronary arteries), leading to a block of excitation–contraction coupling and a relaxation of the vasculature. They also inhibit L-type channel-mediated calcium influx into cardiomyocytes and thus inhibit the cardiac action potential. The cardiac pacemaker activity may be brought about by the inhibition of calcium channels (including the T-type channel) in the sinoatrial node as well as the atrioventricular node. After identification and cloning of other VGCC, many therapeutically used calcium antagonists have been evaluated for efficacy on these channels, and it has become clear that many calcium antagonists are not selective for the L-type channel (Fujii *et al.*, 1997; Furukawa *et al.*, 1997).

For example, verapamil, nifedipine and nimodipine block ω -conotoxin GVIA-insensitive and ω -agatoxin IVA-sensitive currents in dorsal root ganglion cells, indicating N- and P/Q-blockade (Diochot *et al.*, 1995). Effective concentrations were in the micromolar range and several-fold higher than for L-type block. Verapamil and diltiazem block P-type currents in cerebellar Purkinje neurons (Ishibashi *et al.*, 1995), and diltiazem may shift the P-type inactivation curve. It was later shown that verapamil blocks P-type currents as well as other high voltage-gated calcium currents in rat striatal slices. Diltiazem also blocks P-type currents in this system (Dobrev *et al.*, 1999). Diltiazem also blocks P/Q-type channels recombinantly expressed in HEK293 cells, although it is five-fold less potent than on L-type channels (Hockerman *et al.*, 2000). Interestingly, when P/Q-type channels containing a nine-amino acid sequence specific for the dihydropyridine binding site were expressed, diltiazem reached the same potency at P/Q-type channels as at L-type channels. Mansvelder *et al.* (1996) published a study showing that ω -conotoxin GVIA and ω -Agatoxin IVA-sensitive currents are

Table 3

Clinically used compounds with P/Q channel activity (in alphabetical order)

Compound	Primary indication(s)	Suggested primary target mediating clinical efficacy	Reference
Amlodipine	Hypertension, angina pectoris	L-type channel	Haria and Wagstaff, 1995; Scholz, 1997
Barnidipine	Hypertension	L-type channel	Liau 2005
Diltiazem	Hypertension, angina pectoris, cardiac arrhythmias	L-type channel	McAuley and Schroeder, 1982
Flunarizine	Migraine	VGCC, Na ⁺ channels	Amery, 1983; Ye <i>et al.</i> , 2011
Fluspirilene	Schizophrenia	Dopamine D ₂ receptors	Galizzi <i>et al.</i> , 1986
Gabapentin	Epilepsy, neuropathic pain	$\alpha 2\delta$ subunit of VGCC	Striano and Striano, 2008
Halothane	Inhalation anaesthesia	Multiple modes of action	Krnjević, 1992
Isoflurane	Inhalation anaesthesia	Multiple modes of action	Krnjević, 1992
Isoprenaline	Bradycardia, heart block, asthma	β -adrenoceptor	Ahlquist, 1976
Lamotrigine	Epilepsy	Na ⁺ channels, VGCC	Rogawski and Löscher, 2004; Elger and Schmidt, 2008
Levetiracetam	Epilepsy	VGCC, SV2	Elger and Schmidt, 2008
Memantine	Alzheimer's disease	NMDA receptor	Rogawski and Wenk, 2003
Mibefradil	Hypertension	T-type channel	Glasser, 1998
Nicardipine	Hypertension	L-type channel	Pepine and Lambert, 1990
Nimodipine	Cerebral vasospasm after subarachnoid haemorrhage	L-type channel	Tomassoni <i>et al.</i> , 2008
Verapamil	Cardiac arrhythmias, hypertension, angina pectoris	L-type channel	Rosen <i>et al.</i> , 1975; Scholz, 1997

Listed are the primary indications as well as targets suggested to mediate the therapeutic effect. References in column 4 report the pharmacological mechanism suggested to mediate the therapeutic effect.

blocked in rat melanotropic cells by the two dihydropyridines nimodipine and nitrendipine with an IC₅₀ of 200–500 nM. This indicates that both nimodipine and nitrendipine affect N- and P/Q-type currents with appreciable potencies.

A comparative study with 10 dihydropyridines was performed on different calcium channels recombinantly expressed in *Xenopus* oocytes (Furukawa *et al.*, 1999). Nifedipine, nilvadipine, barnidipine, nimodipine, nitrendipine, amlodipine, nicardipine, benidipine, felodipine and cilnidipine all showed appreciable block of L-type channels at 10 μ M. Of these, amlodipine, benidipine, cilnidipine, nicardipine and barnidipine also blocked P/Q- and N-type calcium channels. The P/Q channel block by amlodipine, nicardipine and barnidipine was voltage-dependent. Amlodipine was most potent with an IC₅₀ of 3 μ M at depolarized states (vs. 11.5 μ M at hyperpolarized state). Similar potencies were observed for benidipine, cilnidipine and barnidipine. Some calcium antagonists, like cilnidipine, exhibited a similar block of L-, P/Q- and N-type currents at 10 μ M. In contrast to the two studies on native currents described above (Diochot *et al.*, 1995; Mansvelder *et al.*, 1996), nimodipine had only a minor and nitrendipine no effect on P/Q-type channels. An explanation for this contrasting result could be the use of recombinant versus native test systems.

Taken together, these data indicate that several classes of therapeutically used 'calcium antagonists' are not specific to

the L-type channel of smooth muscle, but also affect other calcium channels including the P/Q-type channel. Further studies need to examine whether their activity on N- and P/Q-type calcium channels explains some of the clinical findings, especially the efficacy in some neurological disorders discussed below.

We recently reported that A β globulomer, an oligomeric peptide with a toxic epitope found in AD patients, increases P/Q-type calcium currents recombinantly expressed in *Xenopus* oocytes (Mezler *et al.*, 2012a). A similar increase in P/Q-type channel activity has also been observed by Ramsden *et al.* (2002) and MacManus *et al.* (2000) in cultured neurons, albeit with less relevant A β preparations. It has been suggested A β oligomers enhance calcium channel flux through P/Q-type channels. Tonically overactive P/Q-type channels at central synapses may cause excessive glutamate release in affected brain regions, leading to excitotoxic cell death (Mezler *et al.*, 2012a). Such neuronal decline should be prevented by P/Q-type channel block. The neuroprotective effect of P/Q-type channel blockers has been thoroughly described in the literature (e.g. Small *et al.*, 1995; Asakura *et al.*, 1997). A few reports state that nimodipine is protective against AD (Tollefson, 1990; Grobe-Einsler and Traber, 1992), although the effect is minimal. Some efficacy of nimodipine in dementia trials was also stated in a Cochrane Review (López-Arrieta and Birks, 2002). Clinical improvement of cognitive decline was observed after treatment with nicardipine (Amenta *et al.*,

2009). In a nucleus basalis lesion model in rats, verapamil was efficacious in the behavioural outcome (Popović *et al.*, 1997).

P/Q block by verapamil may also explain why a particular type of stroke caused by a mutation in the gene for the P/Q-type calcium channel responds to treatment with verapamil (case report: Knierim *et al.*, 2011). This type of recurrent stroke is associated with seizures and may be prevented by P/Q channel inhibition because of a down-regulation of neuronal firing.

A number of calcium antagonists that are not classically related to the L-type channel block, also show P/Q channel activity. Mibefradil is considered to be a selective T-type calcium channel blocker and is used clinically for the treatment of hypertension. It also has been shown to exhibit some activity for the N-type and P/Q-type channel (Viana *et al.*, 1997).

Flunarizine is a mixed sodium and calcium channel blocker clinically used for the treatment of migraine. Flunarizine blocks P-type currents in neocortical slices, thereby preventing potassium-stimulated calcium influx with an IC_{50} of 11 μ M (Geer *et al.*, 1993). In cultured cortical neurons, the calcium channel block was more potent with an IC_{50} of 1.77 μ M, which is similar to the potency at the sodium channel (IC_{50} 0.94 μ M; Ye *et al.*, 2011). Certain types of familial migraines are caused by mutations in the CACNA1A subunit of the P/Q-type channel. Expression of these mutants in transgenic mice leads to enhanced P/Q channel activity and consequently facilitation of cortical spreading depression (Tottene *et al.*, 2009), which is thought to underlie migraine aura. The phenomena of spreading depression can be blocked by ω -agatoxin IVA (Kunkler and Kraig, 2004). It has been shown that flunarizine enhances the threshold for cortical spreading depression (Wauquier *et al.*, 1985), and one may speculate its preventive effect in migraine can at least in part be attributed to block of P/Q-type channels in the brain. Familial migraines caused by P/Q mutations also seem to respond to verapamil (Yu and Horowitz, 2003), as do other migraine types (Solomon *et al.*, 1983; Markley *et al.*, 1984).

In summary, there is evidence that certain clinically used calcium antagonists show therapeutic benefit for some neurological diseases that might be linked to P/Q-type calcium channels. If the clinical effects can be attributed to their shared efficacy on P/Q channels, an improvement in P/Q channel specificity as well as target availability may improve their efficacy for these diseases and may reduce their side effects. As all the substances discussed above affect multiple targets, none of these structures may serve as a real lead compound for the development of selective P/Q-type channel blockers.

Antiepileptic drugs. Epileptic seizures are generally caused by a shift in the excitation/inhibition balance in cortical networks towards excitation. This involves enhanced neurotransmission at glutamatergic synapses, which is at least in part mediated by P/Q-type channels (Qian and Noebels, 2001). There is increasing evidence that VGCC, including P/Q-type channels, contribute to idiopathic generalized epilepsies (Zamponi *et al.*, 2010). Mutations in P/Q-type calcium channels have also been linked to absence seizures. Some anti-epileptic drugs interact with the $\alpha 2\delta$ accessory subunit of

VGCC (Vohora *et al.*, 2010). For some, a direct P/Q-type current modulation has been shown. Levetiracetam has been demonstrated to inhibit high-voltage-gated calcium currents in hippocampal pyramidal neurons in slices (Niespodziany *et al.*, 2001). It has also recently been shown to block excitatory postsynaptic potentials in granule cells in slices specifically by blocking the P/Q-type calcium current (Lee *et al.*, 2009). Levetiracetam reduces N- and P/Q-type currents in isolated neocortical neurons without affecting sodium currents at 100 μ M, a concentration that attenuates the paroxysmal depolarization shift in a neocortical slice model of epilepsy (Pisani *et al.*, 2004). Lamotrigine also inhibits high-threshold voltage-gated calcium currents with an IC_{50} of 12.3 μ M in isolated rat pyramidal neurons (Stefani *et al.*, 1996a), which is attributed to N- and P-type blockade. Older antiepileptic drugs like carbamazepin and oxcarbazepine are also active on high threshold calcium currents (Stefani *et al.*, 1995; Zhu *et al.*, 2002), and it has been suggested that carbamazepine has P/Q-activity (Zhu *et al.*, 2002). Some anti-epileptics like felbamate also affect high VGCCs, but not the P/Q-type calcium channel (Stefani *et al.*, 1996b), whereas other anti-epileptics have little effect on high-threshold VGCC (phenytoin; Stefani *et al.*, 1997). Valproate does not seem to have any effect on presynaptic calcium channels, even at very high concentrations (up to 1.5 mM; Sitges *et al.*, 2007).

Gabapentin and pregabalin comprise a class of molecules that bind to the $\alpha 2\delta$ accessory subunit of VGCC with nanomolar affinities (Suman-Chauhan *et al.*, 1993; Gee *et al.*, 1996). It is thus not surprising that there are multiple studies showing a modulation of VGCC by those drugs. Some authors consider them to be selective for VGCC (reviewed by Sills, 2006). Both, gabapentin and pregabalin, at μ M concentrations, attenuate neurotransmitter release in cortical slices by inhibition of P/Q-type channels (Dooley *et al.*, 2002). In cortical synaptosomes, gabapentin also blocks the ω -agatoxin IVA-sensitive increase in potassium-induced calcium levels in the μ M range (Fink *et al.*, 2002). In addition, it blocks P/Q-type (and N-type) channels in rat cerebrocortical slices with an IC_{50} (for P/Q) of 98 μ M (Oka *et al.*, 2003a). In another study, Oka *et al.* (2003b) analysed the effect of gabapentin on depolarization-evoked NOS activity in primary cortical neurons. High concentrations of gabapentin (100 μ M) reduced depolarization-induced NOS activity by blockade of P/Q-type and L-type (not N-type) calcium channels. Gabapentin reduced presynaptic vesicle release at low μ M concentrations, preferably acting via P/Q-type channel block (Cunningham *et al.*, 2004). Gabapentin also reduced EPSCs and IPSCs in spinal cord, with an IC_{50} of 23 nM, by reducing P/Q-type calcium currents (Bayer *et al.*, 2004). Whole-cell recordings from dorsal root ganglion cells revealed that gabapentin blocks all N-, P/Q- and L-type channels (Sutton *et al.*, 2002), although the P/Q block appears to be the smaller part. Kang *et al.* (2002), when recording from P/Q channels recombinantly expressed in *Xenopus* oocytes, found that chronic but not acute treatment with gabapentin induced a dose-dependent decrease in P/Q-type current inactivation. Inactivation kinetics were modified at concentrations starting at 300 nM. In this respect, it should be noted that the $\alpha 2\delta$ subunit has been shown to modulate calcium channel kinetics (Qin *et al.*, 1998).

As described above, both familiar migraines as well as A β pathology involve a gain-of-function in the P/Q-type current. Thus, it may not come as a surprise that some anti-epileptics are efficacious in these conditions. Piracetam (Croisile *et al.*, 1993) and levetiracetam (Cumbo and Ligori, 2010) are also efficacious in AD patients. Treatment with levetiracetam has been correlated with improved cognitive performance, whereas piacetam seems to slow down cognitive decline. Similarly, levetiracetam appears to be beneficial in patients with migraine (Pizza *et al.*, 2011). A number of studies also report efficacy of gabapentin as a prophylactic in migraine (e.g. Di Trapani *et al.*, 2000; Mathew *et al.*, 2001), which may be explained by the ability of the calcium channel blocker gabapentin to prevent cortical spreading depression (Hoffmann *et al.*, 2010).

Mood stabilizers. Calcium channel blockers have been suggested to be beneficial in the treatment of bipolar disorder (Levy and Janicak, 2000). While for some drugs of this class the efficacy has been questioned, data for nimodipine have appeared promising (Pazzaglia *et al.*, 1998). This could be attributed to a better brain penetration by nimodipine as opposed to other calcium channel blockers. It is also possible that nimodipine exhibits different modulatory effects on calcium channels. Whether block of P/Q-type calcium channels contributes to the mood stabilizing properties is unclear. Some data suggest that modulation of presynaptic calcium influx may positively influence bipolar disorder. For example, Chen *et al.* (2010) implicate presynaptic glutamate release in the pathophysiology of bipolar disorder. Patients with bipolar disorder have been shown to have an increased neurotransmission in the anterior cingulate cortex (Eastwood and Harrison, 2010). Animal studies are needed to clarify whether a specific block of P/Q-type channels could ameliorate symptoms of bipolar disorder.

Anaesthetics. Volatile anaesthetics inhibit P/Q-type currents in the higher μ M range, although the block is not specific for this channel isoform. Both isoflurane and halothane increase the rate of inactivation in P/Q-type currents recombinantly expressed in *Xenopus* oocytes (Kamatchi *et al.*, 1999). Isoflurane also inhibits P/Q-type, N-type and L-type calcium currents in dorsal root ganglion cells (Kameyama *et al.*, 1999) and probably in hippocampal pyramidal cells (Study, 1994). Volatile anaesthetics including halothane prevent glutamate release evoked in synaptosomes via a presynaptic mechanism (Schlame and Hemmings, 1995).

It is generally thought that volatile anaesthetics affect multiple targets in the brain with low potency, including GABA_A receptors and VGCC. Thus, it is likely that P/Q channel block has – if at all – a minor contribution to the general anaesthetic state.

Antipsychotics. A number of dopamine receptor antagonists exhibit P-type channel activity, unrelated to a specific structure (Sah and Bean, 1994). Diphenylbutylpiperidines have long been known to exhibit calcium channel activity (Gould *et al.*, 1983) and compromise the activity of the most potent calcium channel blockers (Sah and Bean, 1994). They bind to calcium channels with affinities in the low nM range (Gould

et al., 1983). Of all these compounds, fluspirilene is the most potent P-type current blocker, with an IC₅₀ of 6 μ M. This block is not specific to P-type channels but also affects N-, L- and T-type channels (Sah and Bean, 1994). At a higher concentration (30 μ M), most neuroleptic drugs, including chlorpromazine and haloperidol, have considerable activity on P-type currents. However, these concentrations may not be relevant for antipsychotic activity. As some neuroleptics show the ability to act as a calmodulin antagonist, the effect of fluspirilene was studied in the presence of the calcium chelator BAPTA, but this did not change its potency. Its effect was also not mediated by neurotransmitter activation of G-proteins (that are known to modulate P-type channels). However, the block of P-type currents by fluspirilene was voltage- and frequency dependent (Sah and Bean, 1994). Hence, the binding site of fluspirilene seems to be different from that of ω -agatoxin-IVA and also different from that of the pore blocker Cd²⁺.

Herbal medication. Some plant extracts that are used as prophylactics for migraine (Diener *et al.*, 2004; Lipton *et al.*, 2004) also inhibit P/Q-type channels. α -Eudesmol (*Eucalyptus williamsiana*) and petasins (*Petasites hybridus*) state-dependently inhibit recombinant P/Q-type currents (Horak *et al.*, 2009). In rat cerebellar Purkinje cells, eudesmol (*Juni-perus virginiana*) inhibits P/Q-type currents with an IC₅₀ of 3.6 μ M (Asakura *et al.*, 1999). However, whether the ability of these substances to affect P/Q-type currents is therapeutically relevant is questionable.

Is there a path for the development of a selective P/Q-type channel blocker?

One of the challenges in drug discovery is the development of a lead compound with sufficient selectivity for the target. In this respect, VGCCs may be at the extreme end of the spectrum, as selectivity for some types appears to be extremely difficult to obtain. Consequently, there are few fully selective calcium channel blockers. For the development of selective P/Q-type channel blockers, sparse information on structure–activity relationships and perhaps limited high-throughput electrophysiological methods may have hampered the development of the appropriate lead molecule in the past. The pharmaceutical industry has initiated drug discovery programmes for low molecular weight N-type channel blockers, which was inspired by the approval of the selective peptide N-type channel blocker ziconotide for chronic pain. Yet, no small lead molecule with appreciable selectivity for a presynaptic calcium channel has been forwarded into clinical trials.

Recently, some progress has been made by the pharmaceutical industry to separate N- and P/Q-type blockade from L-type channel activity. Abbott Laboratories, for example, recently presented a small lead molecule – A-1048400 – with high potency for the N-, P/Q- and T-type channel, but which is largely devoid of L-type channel activity (Scott *et al.*, 2012). Separation from L-type channel activity was also reached by Neuromed Pharmaceuticals (see Table 2). Anecdotal reports also indicate separation of N and P/Q channel activity. Neuromed have described a number of compounds that show some selectivity for the N-type versus the P/Q-type channel (e.g. Neuromed 5). Beedle and Zamponi (2000) report that a

small molecule – dodecylamine – is largely selective for P/Q-type channels. However, these reports do not provide a clear structure–activity relationship for a development path for small P/Q channel blockers.

An alternative would be a development programme based on one of the two selective peptide P/Q-type channel blockers, ω -agatoxin IVA and ω -agatoxin IVB – in analogy to the N-type blocker ziconotide (Schmidtko *et al.*, 2010). For a number of reasons, ω -agatoxins themselves may not be suitable for CNS therapeutics: firstly, their pharmacokinetic properties are not suitable for oral administration and sufficient brain availability is still an illusion. The latter would be required for the treatment of potentially P/Q channel-related disorders like migraine or AD. Medicinal chemistry approaches have recently succeeded in modifying peptide toxins by cyclization to improve their biophysical properties (for review, see Craik and Adams, 2007). Yet, good bioavailability of peptide toxins is still a challenge, and these molecules do not penetrate the blood–brain barrier. Secondly, administration of ω -agatoxin may have strong adverse effects, as it blocks the channel largely irreversibly (unblock occurs only at large depolarizations; Adams *et al.*, 1993). However, structural information from the binding domain of ω -agatoxin IVA and ω -agatoxin IVB may be a basis for the development of selective and more appropriate peptide analogues. The C-terminal domain of ω -agatoxin IVA has been identified as the active peptide part for P/Q channel blockade (Kim *et al.*, 1995). Some information on active parts of the peptide has also been obtained for ω -agatoxin IVB (Adams *et al.*, 1993). Narrowing down an amino acid sequence to the minimal active motif may provide a basis for the development of peptidomimetics with appropriate pharmacokinetic properties. For ω -conotoxins, channel activity has been to some degree attributed to two conserved amino acid residues Tyr¹³ and Lys² (Sato *et al.*, 1993; Kim *et al.*, 1994), together with other residues in loop 2 and 4 (for overview, see Lewis *et al.*, 2012). Lys¹⁰ and Arg²², as well as a number of positively charged residues in loops 2 and 4, seem to influence subtype selectivity for the P/Q-type channel (Haack *et al.*, 1993; Nielsen *et al.*, 1999b). There have been encouraging reports on N-type peptide mimetics showing that the development of a pharmacophore in drug discovery based on toxin peptide information is principally possible. Baell *et al.* (2004) generated peptide mimetics for N-type channel blockers based on the peptide information from ω -conotoxin GVIA. One analogue, compound 4a, mimics three side chains of this peptide and potently blocks N-type calcium channels in the micromolar range. It also retains some selectivity over the P/Q-type channel (approx. 20-fold). Parke-Davis (now Pfizer) designed a small-molecule N-type channel blocker mimicking three residues of ω -conotoxin MIIA (Menzler *et al.*, 2000). Further development also resulted in the generation of an orally-available small-molecule blocker with improved physicochemical properties (e.g. Hu *et al.*, 2000).

A different approach to achieving a selective P/Q-type channel blocker is to address the binding site for selective P/Q channel blockers at the channel. For ω -agatoxin IVA, at least (Winterfield and Swartz, 2000), and possibly kurtosin (Sidach and Mintz, 2002), this site has been localized and is thought to be the S3-S4 linker at the outer mouth of the pore. A displacement assay using a selective ω -agatoxin-based radio-

ligand could be implemented into a high throughput screening. However, this requires the selective small molecules to be actually available in synthetic compound libraries.

Conclusions

The aim of this review was to provide an overview of the vast number of compounds that modulate the P/Q-type channel. Currently, there are only two selective molecules available, which are peptide blockers derived from spider venom. All other compounds discussed here are nonselective, and their activity on other targets is often higher than that on P/Q-type channels. Yet, the knowledge of the distinct profile of each of those compounds is necessary to interpret and design experiments, and perhaps to analyse clinical studies. Knowledge about the spectrum of targets of each of the classical calcium antagonists may also challenge the view that all of the observed effects in animal models and clinical trials are mediated by L-type channel blockade.

Currently, there is not sufficient information on structure–activity relationships available for a focused development of P/Q channel blockers. Recent advances in high-throughput electrophysiological techniques may facilitate screening for small molecules with higher selectivity. Perhaps one may draw hope from peptide chemistry efforts to create P/Q-type specific peptide mimetics with improved pharmacokinetic profiles.

The development of P/Q-type selective tool compounds and lead molecules with sufficient bioavailability and brain penetration will clearly remain a challenge.

Acknowledgements

This review article was supported by Abbott.

Statement of conflicts of interest

None.

References

- Abbadie C, McManus OB, Sun SY, Bugianesi RM, Dai G, Haedo RJ *et al.* (2010). Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. *J Pharmacol Exp Ther* 334: 545–555.
- Abramov E, Dolev I, Fogel H, Cicciotosto GD, Ruff E, Slutsky I (2009). Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. *Nat Neurosci* 12: 1567–1576.
- Adams ME (2004). Agatoxins: ion channel specific toxins from the American funnel web spider, *Agelenopsis aperta*. *Toxicon* 43: 509–525.
- Adams ME, Mintz IM, Reily MD, Thanabal V, Bean BP (1993). Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels. *Mol Pharmacol* 44: 681–688.

- Ahlquist RP (1976). Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. *Am Heart J* 92: 661–664.
- Aldoss IT, Tashi T, Ganti AK (2009). Seliciclib in malignancies. *Expert Opin Investig Drugs* 18: 1957–1965.
- Amenta F, Lanari A, Mignini F, Silvestrelli G, Traini E, Tomassoni D (2009). Nicardipine use in cerebrovascular disease: a review of controlled clinical studies. *J Neurol Sci* 283: 219–223.
- Amery WK (1983). Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. *Headache* 23: 70–74.
- Arroyo G, Aldea M, Fuentealba J, Albillos A, García AG (2003). SNX482 selectively blocks P/Q Ca²⁺ channels and delays the inactivation of Na⁺ channels of chromaffin cells. *Eur J Pharmacol* 475: 11–18.
- Asakura K, Matsuo Y, Kanemasa T, Ninomiya M (1997). P/Q-type Ca²⁺ channel blocker omega-agatoxin IVA protects against brain injury after focal ischemia in rats. *Brain Res* 776: 140–145.
- Asakura K, Kanemasa T, Minagawa K, Kagawa K, Ninomiya M (1999). The nonpeptide alpha-eudexp6l from *Juniperus virginiana* Linn. (Cupressaceae) inhibits omega-agatoxin IVA-sensitive Ca²⁺ currents and synaptosomal 45Ca²⁺ uptake. *Brain Res* 823: 169–176.
- Baell JB, Duggan PJ, Forsyth SA, Lewis RJ, Lok YP, Schroeder CI (2004). Synthesis and biological evaluation of nonpeptide mimetics of omega-conotoxin GVIA. *Bioorg Med Chem* 12: 4025–4037.
- Bayer K, Ahmadi S, Zeilhofer HU (2004). Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca²⁺ channels. *Neuropharmacology* 46: 743–749.
- Beedle AM, Zamponi GW (2000). Block of voltage-dependent calcium channels by aliphatic monoamines. *Biophys J* 79: 260–270.
- Benquet P, Guen JL, Dayanithi G, Pichon Y, Tiaho F (1999). omega-AgaIVA-sensitive (P/Q-type) and -resistant (R-type) high-voltage-activated Ba(2+) currents in embryonic cockroach brain neurons. *J Neurophysiol* 82: 2284–2293.
- Biton B, Granger P, Carreau A, Depoortere H, Scatton B, Avenet P (1994). The NMDA receptor antagonist eliprodil (SL 82.0715) blocks voltage-operated Ca²⁺ channels in rat cultured cortical neurons. *Eur J Pharmacol* 257: 297–301.
- Biton B, Granger P, Depoortere H, Scatton B, Avenet P (1995). Block of P-type Ca²⁺ channels by the NMDA receptor antagonist eliprodil in acutely dissociated rat Purkinje cells. *Eur J Pharmacol* 294: 91–100.
- Bourinet E, Soong TW, Sutton K, Slaymaker S, Mathews E, Monteil A *et al.* (1999). Splicing of alpha 1A subunit gene generates phenotypic variants of P- and Q-type calcium channels. *Nat Neurosci* 2: 407–415.
- Bourinet E, Stotz SC, Spaetgens RL, Dayanithi G, Lemos J, Nargeot J *et al.* (2001). Interaction of SNX482 with domains III and IV inhibits activation gating of alpha(1E) (Ca(V)2.3) calcium channels. *Biophys J* 81: 79–88.
- Bresink I, Benke TA, Collett VJ, Seal AJ, Parsons CG, Henley JM *et al.* (1996). Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. *Br J Pharmacol* 119: 195–204.
- Brown EM, Fedak SA, Woodard CJ, Aurbach GD (1976). Beta-Adrenergic receptor interactions. Direct comparison of receptor interaction and biological activity. *J Biol Chem* 251: 1239–1246.
- Buraei Z, Elmslie KS (2008). The separation of antagonist from agonist effects of trisubstituted purines on CaV2.2 (N-type) channels. *J Neurochem* 105: 1450–1461.
- Buraei Z, Schofield G, Elmslie KS (2006). Roscovitine differentially affects CaV2 and Kv channels by binding to the open state. *Neuropharmacology* 52: 883–894.
- Cassola AC, Jaffe H, Fales HM, Afeche SC, Magnoli F, Cipolla-Neto J (1998). ω-Phonetoxin-IIA: a calcium channel blocker from the spider *Phoneutria nigriventer*. *Pflügers Arch* 436: 545–552.
- Chen G, Henter ID, Manji HK (2010). Presynaptic glutamatergic dysfunction in bipolar disorder. *Biol Psychiatry* 67: 1007–1009.
- Cho S, Meriney SD (2006). The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. *Eur J Neurosci* 23: 3200–3208.
- Clark RJ, Fischer H, Dempster L, Daly NL, Rosengren KJ, Nevin ST *et al.* (2005). Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII. *Proc Natl Acad Sci U S A* 102: 13767–13772.
- Craik DJ, Adams DJ (2007). Chemical modification of conotoxins to improve stability and activity. *ACS Chem Biol* 2: 457–468.
- Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M (1993). Long-term and high-dose piracetam treatment of Alzheimer's disease. *Neurology* 43: 301–305.
- Cumbo E, Lorigi LD (2010). Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. *Epilepsy Behav* 17: 461–466.
- Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS (2004). Dual effects of abapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. *Eur J Neurosci* 20: 1566–1576.
- Di Trapani G, Mei D, Marra C, Mazza S, Capuano A (2000). Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. *Clin Ter* 151: 145–148.
- Diener HC, Rahlfs VW, Danesch U (2004). The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. *Eur Neurol* 51: 89–97.
- Diochot S, Richard S, Baldy-Moulinier M, Nargeot J, Valmier J (1995). Dihydropyridines, phenylalkylamines and benzothiazepines block N-, P/Q- and R-type calcium currents. *Pflügers Arch* 431: 10–19.
- Dobrev D, Milde AS, Andreas K, Ravens U (1999). The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum. *Br J Pharmacol* 127: 576–582.
- Dolphin AC (2009). Calcium channel diversity: multiple roles of calcium channel subunits. *Curr Opin Neurobiol* 19: 1–8.
- Dooley DJ, Donovan CM, Meder WP, Whetzel SZ (2002). Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K⁺-evoked [3H]-norepinephrine release from rat neocortical slices. *Synapse* 45: 171–190.
- Dos Santos RG, Van Renterghem C, Martin-Moutot N, Mansuelle P, Cordeiro MN, Diniz CR *et al.* (2002). Phoneutria nigriventer omega-phonetoxin IIA blocks the Cav2 family of calcium channels and interacts with omega-conotoxin-binding sites. *J Biol Chem* 277: 13856–13862.
- Eastwood SL, Harrison PJ (2010). Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. *Biol Psychiatry* 67: 1010–1016.

- Elger CE, Schmidt D (2008). Modern management of epilepsy: a practical approach. *Epilepsy Behav* 12: 501–539.
- Ellis DJ, Dissanayake S, McGuire D, Charapata SG, Staats PS, Wallace MS *et al.* (2008). Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: a prospective, open-label study. *Neuromodulation* 11: 40–49.
- Enyeart JJ, Biagi BA, Mlinar B (1992). Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines. *Mol Pharmacol* 42: 364–372.
- Ertel EA, Smith MM, Leibowitz MD, Cohen CJ (1994). Isolation of myocardial L-type calcium channel gating currents with the spider toxin omega-Aga-IIIa. *J Gen Physiol* 103: 731–753.
- Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H *et al.* (2002). Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. *Neuropharmacology* 42: 229–236.
- Fleckenstein-Grün G (1994). Historical development of calcium antagonism- in memoriam Albrecht Fleckenstein. *High Blood Press* 3: 284–290.
- Fletcher CF, Lutz CM, O'Sullivan TN, Shaughnessy JD Jr, Hawkes R, Frankel WN *et al.* (1996). Absence epilepsy in tottering mutant mice is associated with calcium channel defects. *Cell* 87: 607–617.
- Fletcher CF, Tottene A, Lennon VA, Wilson SM, Dubel SJ, Paylor R *et al.* (2001). Dystonia and cerebellar atrophy in *Cacna1a* null mice lacking P/Q calcium channel activity. *FASEB J* 15: 1288–1290.
- Freir DB, Costello DA, Herron CE (2003). A beta 25-35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. *J Neurophysiol* 89: 3061–3069.
- Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K (1997). Effect of cilnidipine, a novel dihydropyridine Ca⁺⁺-channel antagonist, on N-type Ca⁺⁺ channel in rat dorsal root ganglion neurons. *J Pharmacol Exp Ther* 280: 1184–1191.
- Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M *et al.* (1997). Voltage and pH dependent block of cloned N-type Ca²⁺ channels by amlodipine. *Br J Pharmacol* 121: 1136–1140.
- Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T (1999). Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in *Xenopus* oocytes. *J Pharmacol Exp Ther* 291: 464–473.
- Galizzi JP, Fosset M, Romey G, Laduron P, Lazdunski M (1986). Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors. *Proc Natl Acad Sci U S A* 83: 7513–7517.
- Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN (1996). The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. *J Biol Chem* 271: 5768–5776.
- Geer JJ, Dooley DJ, Adams ME (1993). K(+)-stimulated 45Ca²⁺ flux into rat neocortical mini-slices is blocked by omega-Aga-IVA and the dual Na⁺/Ca²⁺ channel blockers lidoflazine and flunarizine. *Neurosci Lett* 158: 97–100.
- Glasser SP (1998). The relevance of T-type calcium antagonists: a profile of mibefradil. *J Clin Pharmacol* 38: 659–669.
- Gould RJ, Murphy KM, Reynolds IJ, Snyder SH (1983). Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. *Proc Natl Acad Sci U S A* 80: 5122–5125.
- Grobe-Einsler R, Traber J (1992). Clinical results with nimodipine in Alzheimer disease. *Clin Neuropharmacol* 15 (Suppl. 1): 416A–417A.
- Haack JA, Kinser P, Yoshikami D, Olivera BM (1993). Biotinylated derivatives of omega-conotoxins GVIA and MVIID: probes for neuronal calcium channels. *Neuropharmacology* 32: 1151–1159.
- Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B *et al.* (2001). Mechanisms of migraine aura revealed by functional MRI in human visual cortex. *Proc Natl Acad Sci U S A* 98: 4687–4692.
- Han TS, Teichert RW, Olivera BM, Bulaj G (2008). Conus venoms – a rich source of peptide-based therapeutics. *Curr Pharm Des* 14: 2462–2479.
- Hans M, Urrutia A, Deal C, Brust PF, Staudermann K, Ellis SB *et al.* (1999). Structural elements in domain IV that influence biophysical and pharmacological properties of human α_{1A} -containing high-voltage-activated calcium channels. *Biophys J* 76: 1384–1400.
- Haria M, Wagstaff AJ (1995). Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. *Drugs* 50: 560–586.
- He LM, Chen LY, Lou XL, Qu AL, Zhou Z, Xu T (2002). Evaluation of beta-amyloid peptide 25-35 on calcium homeostasis in cultured rat dorsal root ganglion neurons. *Brain Res* 939: 65–75.
- Heinke B, Balzer E, Sandkühler J (2004). Pre- and postsynaptic contributions of voltage-dependent Ca²⁺ channels to nociceptive transmission in rat spinal lamina I neurons. *Eur J Neurosci* 19: 103–111.
- Hillyard DR, Monje VD, Mintz IM, Bean BP, Nadasdi L, Ramachandran J *et al.* (1992). A new Conus peptide ligand for mammalian presynaptic Ca²⁺ channels. *Neuron* 9: 69–77.
- Hockerman GH, Dilmac N, Scheuer T, Catterall WA (2000). Molecular determinants of diltiazem block in domains III/IV and IV/IV of L-type Ca(2+) channels. *Mol Pharmacol* 58: 1264–1270.
- Hoffmann U, Dileköz E, Kudo C, Ayata C (2010). Gabapentin suppresses cortical spreading depression susceptibility. *J Cereb Blood Flow Metab* 30: 1588–1592.
- Horak S, Koschak A, Stuppner H, Striessnig J (2009). Use-dependent block of voltage-gated Cav2.1 Ca²⁺ channels by petasins and eudesmol isomers. *J Pharmacol Exp Ther* 330: 220–226.
- Hu LY, Ryder TR, Rafferty MF, Taylor CP, Feng MR *et al.* (2000). The discovery of [1-(4-dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethylbutyl)-phenyl]-[3-methyl-but-2-enyl]-amine, an N-type Ca²⁺ channel blocker with oral activity for analgesia. *Bioorg Med Chem* 8: 1203–1212.
- Huang CC, Hsu KS, Gean PW (1996). Isoproterenol potentiates synaptic transmission primarily by enhancing presynaptic calcium influx via P- and/or Q-type calcium channels in the rat amygdala. *J Neurosci* 16: 1026–1033.
- Huang CC, Wang SJ, Gean PW (1998). Selective enhancement of P-type calcium currents by isoproterenol in the rat amygdala. *J Neurosci* 18: 2276–2282.
- Ishibashi H, Yatani A, Akaike N (1995). Block of P-type Ca²⁺ channels in freshly dissociated rat cerebellar Purkinje neurons by diltiazem and verapamil. *Brain Res* 695: 88–91.
- Ishikawa T, Kaneko M, Shin HS, Takahashi T (2005). Presynaptic N-type and P/Q-type Ca²⁺ channels mediating synaptic transmission at the calyx of Held of mice. *J Physiol* 568: 199–209.
- Jones MV, Brooks PA, Harrison NL (1992). Enhancement of gamma-aminobutyric acid-activated Cl⁻ currents in cultured rat hippocampal neurones by three volatile anaesthetics. *J Physiol* 449: 279–293.

- Jun K, Piedras-Rentería ES, Smith SM, Wheeler DB, Lee SB, Lee TG *et al.* (1999). Ablation of P/Q-type Ca^{2+} channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the $\alpha(1A)$ -subunit. *Proc Natl Acad Sci U S A* 96: 15245–15250.
- Kamatchi GL, Chan CK, Snutch T, Durieux ME, Lynch C 3rd (1999). Volatile anesthetic inhibition of neuronal Ca channel currents expressed in *Xenopus* oocytes. *Brain Res* 831: 85–96.
- Kameyama K, Aono K, Kitamura K (1999). Isoflurane inhibits neuronal Ca^{2+} channels through enhancement of current inactivation. *Br J Anaesth* 82: 402–411.
- Kang MG, Felix R, Campbell KP (2002). Long-term regulation of voltage-gated Ca^{2+} channels by gabapentin. *FEBS Lett* 528: 177–182.
- Kass RS (1987). Voltage-dependent modulation of cardiac calcium channel current by optical isomers of Bay K 8644: implications for channel gating. *Circ Res* 61: I1–I5.
- Khosravani H, Zamponi GW (2006). Voltage-gated calcium channels and idiopathic generalized epilepsies. *Physiol Rev* 86: 941–966.
- Kim JI, Takahashi M, Ogura A, Kohno T, Kudo Y, Sato K (1994). Hydroxyl group of Tyr13 is essential for the activity of omega-conotoxin GVIA, a peptide toxin for N-type calcium channel. *J Biol Chem* 269: 23876–23878.
- Kim JI, Konishi S, Iwai H, Kohno T, Gouda H, Shimada I *et al.* (1995). Three-dimensional solution structure of the calcium channel antagonist omega-agatoxin IVA: consensus molecular folding of calcium channel blockers. *J Mol Biol* 250: 659–671.
- Kisilevsky AE, Zamponi GW (2008). Presynaptic calcium channels: structure, regulators, and blockers. *Handb Exp Pharmacol* 184: 45–75.
- Knierim E, Leisle L, Wagner C, Weschke B, Lucke B, Bohner G *et al.* (2011). Recurrent stroke due to a novel voltage sensor mutation in Cav2.1 responds to verapamil. *Stroke* 42: e14–e17.
- Koch ED, Olivera BM, Terlau H, Conti F (2004). The binding of kappa-Conotoxin PVIIA and fast C-type inactivation of Shaker K⁺ channels are mutually exclusive. *Biophys J* 86: 191–209.
- Kokubo H, Kaye R, Glabe CG, Yamaguchi H (2005). Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. *Brain Res* 1031: 222–228.
- Krnjević K (1992). Cellular and synaptic actions of general anaesthetics. *Gen Pharmacol* 23: 965–975.
- Kunkler PE, Kraig RP (2004). P/Q Ca^{2+} channel blockade stops spreading depression and related pyramidal neuronal Ca^{2+} rise in hippocampal organ culture. *Hippocampus* 14: 356–367.
- Lampe RA, Defeo PA, Davison MD, Young J, Herman JL, Spreen RC *et al.* (1993). Isolation and pharmacological characterization of omega-grammotoxin SIA, a novel peptide inhibitor of neuronal voltage-sensitive calcium channel responses. *Mol Pharmacol* 44: 451–460.
- Leão RM, Cruz JS, Diniz CR, Cordeiro MN, Beirão PS (2000). Inhibition of neuronal high-voltage activated calcium channels by the omega-phosphatidylcholine nigriventor Tx3-3 peptide toxin. *Neuropharmacology* 39: 1756–1767.
- Lee CY, Chen CC, Liou HH (2009). Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. *Br J Pharmacol* 158: 1753–1762.
- Levy NA, Janicak PG (2000). Calcium channel antagonists for the treatment of bipolar disorder. *Bipolar Disord* 2: 108–119.
- Lewis RJ, Dutertre S, Vetter I, Christie MJ (2012). Conus venom Peptide pharmacology. *Pharmacol Rev* 64: 259–298.
- Liau CS (2005). Barnidipine: a new calcium channel blocker for hypertension treatment. *Expert Rev Cardiovasc Ther* 3: 207–213.
- Lipton RB, Göbel H, Einhüpf KM, Wilks K, Mauskop A (2004). Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. *Neurology* 63: 2240–2244.
- Li-Smerin Y, Hackos DH, Swartz KJ (2000). α -helical structural elements within the voltage-sensing domains of a K⁺ channel. *J Gen Physiol* 115: 33–50.
- Llinás R, Sugimori M, Lin JW, Cherksey B (1989). Blocking and isolation of a calcium channel from neurons in mammals and cephalopods utilizing a toxin fraction (FTX) from funnel-web spider poison. *Proc Natl Acad Sci U S A* 86: 1689–1693.
- López-Arrieta JM, Birks J (2002). Nimodipine for primary degenerative, mixed and vascular dementia. *Cochrane Database Syst Rev* (3): CD000147.
- Lu CW, Lin TY, Wang SJ (2010). Memantine depresses glutamate release through inhibition of voltage-dependent Ca^{2+} entry and protein kinase C in rat cerebral cortex nerve terminals: an NMDA receptor-independent mechanism. *Neurochem Int* 57: 168–176.
- Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A *et al.* (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. *Proc Natl Acad Sci U S A* 101: 9861–9866.
- van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, Cesetti T *et al.* (2004). A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. *Neuron* 41: 701–710.
- MacManus A, Ramsden M, Murray M, Henderson Z, Pearson HA, Campbell VA (2000). Enhancement of (45) Ca^{2+} influx and voltage-dependent Ca^{2+} channel activity by beta-amyloid-(1–40) in rat cortical synaptosomes and cultured cortical neurons. Modulation by the proinflammatory cytokine interleukin-1beta. *J Biol Chem* 275: 4713–4718.
- Mansvelder HD, Stoof JC, Kits KS (1996). Dihydropyridine block of omega-agatoxin IVA- and omega-conotoxin GVIA-sensitive Ca^{2+} channels in rat pituitary melanotrophic cells. *Eur J Pharmacol* 311: 293–304.
- Markley HG, Cheronis JC, Piepho RW (1984). Verapamil in prophylactic therapy of migraine. *Neurology* 34: 973–976.
- Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N *et al.* (2001). Efficacy of gabapentin in migraine prophylaxis. *Headache* 41: 119–128.
- Mathews EA, García E, Santi CM, Mullen GP, Thacker C, Moerman DG *et al.* (2003). Critical residues of the *Caenorhabditis elegans* unc-2 voltage-gated calcium channel that affect behavioral and physiological properties. *J Neurosci* 23: 6537–6545.
- McAuley BJ, Schroeder JS (1982). The use of diltiazem hydrochloride in cardiovascular disorders. *Pharmacotherapy* 2: 121–133.
- McDonough SI, Swartz KJ, Mintz IM, Boland LM, Bean BP (1996). Inhibition of calcium channels in rat central and peripheral neurons by omega-conotoxin MVIIC. *J Neurosci* 16: 2612–2623.
- McDonough SI, Lampe RA, Keith RA, Bean BP (1997). Voltage-dependent inhibition of N- and P-type calcium channels by the peptide toxin omega-grammotoxin-SIA. *Mol Pharmacol* 52: 1095–1104.

- McDonough SI, Boland LM, Mintz IM, Bean BP (2002). Interactions among toxins that inhibit N-type and P-type calcium channels. *J Gen Physiol* 119: 313–328.
- McNaughton NCL, Horridge E, Gleave R, Beswick PJ, Chen YH, Powell AJ *et al.* (2008). Piperazine amide calcium channel blockers such as NMED-160 block Cav2.2, Cav3.2 and Cav1.2 human recombinant calcium channels in both a tonic and use-dependent manner. *FENS Abstr.* 4, 124.24.
- Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N *et al.* (1997). Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. *Eur J Biochem* 243: 527–536.
- Menzler S, Bikker JA, Suman-Chauhan N, Horwell DC (2000). Design and biological evaluation of non-peptide analogues of omega-conotoxin MVIIA. *Bioorg Med Chem Lett* 10: 345–347.
- Mezler M, Barghorn S, Schoemaker H, Gross G, Nimmrich V (2012a). A β oligomer directly modulates P/Q-type calcium currents in *Xenopus* oocytes. *Br J Pharmacol* 165: 1572–1583.
- Mezler M, Hermann D, Swensen AM, Draguhn A, Terstappen GC, Gross G *et al.* (2012b). Development and validation of a fluorescence-based HTS assay for the identification of P/Q-type calcium channel blockers. *Comb Chem High Throughput Screen* 15: 372–385.
- Milhaud D, Fagni L, Bockaert J, Lafon-Cazal M (2002). Inhibition of voltage-gated Ca $^{2+}$ channels by antazoline. *Neuroreport* 13: 1711–1714.
- Mintz IM, Venema VJ, Adams ME, Bean BP (1991). Inhibition of N- and L-type Ca $^{2+}$ channels by the spider venom toxin omega-Aga-IIIa. *Proc Natl Acad Sci U S A* 88: 6628–6631.
- Mintz IM, Venema VJ, Swiderek KM, Lee TD, Bean BP, Adams ME (1992a). P-type calcium channels blocked by the spider toxin omega-Aga-IVA. *Nature* 355: 827–829.
- Mintz IM, Adams ME, Bean BP (1992b). P-type calcium channels in rat central and peripheral neurons. *Neuron* 9: 85–95.
- Monaco EA 3rd, Vallano ML (2005). Roscovitine triggers excitotoxicity in cultured granule neurons by enhancing glutamate release. *Mol Pharmacol* 68: 1331–1342.
- Motin L, Yasuda T, Schroeder CI, Lewis RJ, Adams DJ (2007). Omega-conotoxin CVIB differentially inhibits native and recombinant N- and P/Q-type calcium channels. *Eur J Neurosci* 25: 435–444.
- Nadasdi L, Yamashiro D, Chung D, Tarczy-Hornoch K, Adriaenssens P, Ramachandran J (1995). Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels. *Biochemistry* 34: 8076–8081.
- Nebe J, Vanegas H, Neugebauer V, Schaible HG (1997). Omega-agatoxin IVA, a P-type calcium channel antagonist, reduces nociceptive processing in spinal cord neurons with input from the inflamed but not from the normal knee joint – an electrophysiological study in the rat in vivo. *Eur J Neurosci* 9: 2193–2201.
- Nielsen KJ, Adams DA, Alewood PF, Lewis RJ, Thomas L, Schroeder T (1999a). Effects of chirality at Tyr13 on the structure-activity relationships of omega-conotoxins from *Conus magus*. *Biochemistry* 38: 6741–6751.
- Nielsen KJ, Adams D, Thomas L, Bond T, Alewood PF, Craik DJ *et al.* (1999b). Structure-activity relationships of omega-conotoxins MVIIA, MVIIIC and 14 loop splice hybrids at N and P/Q-type calcium channels. *J Mol Biol* 289: 1405–1421.
- Niespodziany I, Klitgaard H, Margineanu DG (2001). Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. *Neurosci Lett* 306: 5–8.
- Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A *et al.* (2009). Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (A β) assembly from Alzheimer disease brains. *J Biol Chem* 284: 32895–32905.
- Oka M, Itoh Y, Wada M, Yamamoto A, Fujita T (2003a). A comparison of Ca $^{2+}$ channel blocking mode between gabapentin and verapamil: implication for protection against hypoxic injury in rat cerebrocortical slices. *Br J Pharmacol* 139: 435–443.
- Oka M, Itoh Y, Wada M, Yamamoto A, Fujita T (2003b). Gabapentin blocks L-type and P/Q-type Ca $^{2+}$ channels involved in depolarization-stimulated nitric oxide synthase activity in primary cultures of neurons from mouse cerebral cortex. *Pharm Res* 20: 897–899.
- O'Neill MJ, Hicks CA, Ward MA, Osborne DJ, Wishart G, Mathews KS *et al.* (2001). LY393615, a novel neuronal Ca(2+) and Na(+) channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemia. *Brain Res* 888: 138–149.
- Ophoff RA, Terwindt GM, Frants RR, Ferrari MD (1998). P/Q-type Ca $^{2+}$ channel defects in migraine, ataxia and epilepsy. *Trends Pharmacol Sci* 19: 121–127.
- Pazzaglia PJ, Post RM, Ketter TA, Callahan AM, Marangell LB, Frye MA *et al.* (1998). Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. *J Clin Psychopharmacol* 18: 404–413.
- Pepine CJ, Lambert CR (1990). Cardiovascular effects of nicardipine. *Angiology* 41: 978–986.
- Pexton T, Moeller-Bertram T, Schilling JM, Wallace MS (2011). Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. *Expert Opin Investig Drugs* 20: 1277–1284.
- Pietrobon D (2002). Calcium channels and channelopathies of the central nervous system. *Mol Neurobiol* 25: 31–50.
- Pietrobon D (2010). Cav2.1 channelopathies. *Eur J Physiol* 460: 375–393.
- Pisani A, Bonsi P, Martella G, De Persis C, Costa C, Pisani F *et al.* (2004). Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. *Epilepsia* 45: 719–728.
- Pizza V, Busillo V, Agresta A, Bisogno A, Capasso A (2011). Elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam. *Cent Nerv Syst Agents Med Chem* 11: 31–34.
- Plomp JJ, van den Maagdenberg AM, Molenaar PC, Frants RR, Ferrari MD (2001). Mutant P/Q-type calcium channel electrophysiology and migraine. *Curr Opin Investig Drugs* 2: 1250–1260.
- Pluzhnikov K, Vassilevski A, Korolkova Y, Fisyunov A, Iegorova O, Krishtal O *et al.* (2007). omega-Lsp-IA, a novel modulator of P-type Ca $^{2+}$ channels. *Toxicon* 50: 993–1004.
- Popović M, Popović N, Jovanova-Nesić K, Bokonić D, Dobrić S, Rosić N (1997). Open field behavior in nucleus basalis magnocellularis-lesioned rats treated with physostigmine and verapamil. *Int J Neurosci* 91: 181–188.
- Qian J, Noebels JL (2001). Presynaptic Ca $^{2+}$ channels and neurotransmitter release at the terminal of a mouse cortical neuron. *J Neurosci* 21: 3721–3728.

- Qin N, Olcese R, Stefani E, Birnbaumer L (1998). Modulation of human neuronal alpha 1E-type calcium channel by alpha 2 delta-subunit. *Am J Physiol* 274: C1324–C1331.
- Rajakulendran S, Kaski D, Hanna MG (2012). Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS. *Nat Rev Neurol* 8: 86–96.
- Ramsden M, Henderson Z, Pearson HA (2002). Modulation of Ca²⁺ channel currents in primary cultures of rat cortical neurones by amyloid beta protein (1-40) is dependent on solubility status. *Brain Res* 956: 254–261.
- Randall A, Tsien RW (1995). Pharmacological dissection of multiple types of Ca²⁺ channel currents in rat cerebellar granule neurons. *J Neurosci* 15: 2995–3012.
- Rehberg B, Xiao YH, Duch DS (1996). Central nervous system sodium channels are significantly suppressed at clinical concentrations of volatile anesthetics. *Anesthesiology* 84: 1223–1233.
- Rogawski MA, Löscher W (2004). The neurobiology of antiepileptic drugs. *Nat Rev Neurosci* 5: 553–564.
- Rogawski MA, Wenk GL (2003). The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. *CNS Drug Rev* 9: 275–308.
- Rogers JC, Qu Y, Tanada TN, Scheuer T, Catterall WA (1996). Molecular determinants of high affinity binding of alpha-scorpion toxin and sea anemone toxin in the S3-S4 extracellular loop in domain IV of the Na⁺ channel alpha subunit. *J Biol Chem* 271: 15950–15962.
- Rosen MR, Wit AL, Hoffman BF (1975). Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. *Am Heart J* 89: 665–673.
- Rovira C, Arbez N, Mariani J (2002). Abeta(25-35) and Abeta(1-40) act on different calcium channels in CA1 hippocampal neurons. *Biochem Biophys Res Commun* 296: 1317–1321.
- Sah DW, Bean BP (1994). Inhibition of P-type and N-type calcium channels by dopamine receptor antagonists. *Mol Pharmacol* 45: 84–92.
- Sather WA, Tanabe T, Zhang JF, Mori Y, Adams ME, Tsien RW (1993). Distinctive biophysical and pharmacological properties of class A (B1) calcium channel alpha 1 subunits. *Neuron* 11: 291–303.
- Sato K, Park NG, Kohno T, Maeda T, Kim JI, Kato R *et al.* (1993). Role of basic residues for the binding of omega-conotoxin GVIA to N-type calcium channels. *Biochem Biophys Res Commun* 194: 1292–1296.
- Schlame M, Hemmings HC Jr (1995). Inhibition by volatile anesthetics of endogenous glutamate release from synaptosomes by a presynaptic mechanism. *Anesthesiology* 82: 1406–1416.
- Schmidtke A, Lötsch J, Freynhagen R, Geisslinger G (2010). Ziconotide for treatment of severe chronic pain. *Lancet* 375: 1569–1577.
- Scholz H (1997). Pharmacological aspects of calcium channel blockers. *Cardiovasc Drugs Ther* 10 (Suppl. 3): 869–872.
- Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS *et al.* (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. *Psychopharmacology* 124: 57–73.
- Schweitz H, Heurteaux C, Bois P, Moinier D, Romey G, Lazdunski M (1994). Calcicludine, a venom peptide of the Kunitz-type protease inhibitor family, is a potent blocker of high-threshold Ca²⁺ channels with a high affinity for L-type channels in cerebellar granule neurons. *Proc Natl Acad Sci U S A* 91: 878–882.
- Scott VE, Vortherms TA, Niforatos W, Swensen AM, Neelands T, Milicic I *et al.* (2012). A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats. *Biochem Pharmacol* 83: 406–418.
- Sidach SS, Mintz IM (2002). Kurtosin, a gating modifier of neuronal high- and low-threshold Ca channels. *J Neurosci* 22: 2023–2034.
- Sills GJ (2006). The mechanisms of action of gabapentin and pregabalin. *Curr Opin Pharmacol* 6: 108–113.
- Sitges M, Guarneros A, Nekrasov V (2007). Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca²⁺ channel-mediated release of [3H]glutamate: comparison with the Na⁺ channel-mediated release. *Neuropharmacology* 53: 854–862.
- Small DL, Monette R, Mealing G, Buchan AM, Morley P (1995). Neuroprotective effects of omega-Aga-IVA against in vitro ischaemia in the rat hippocampal slice. *Neuroreport* 6: 1617–1620.
- Solem M, McMahon T, Messing RO (1997). Protein kinase A regulates inhibition of N- and P/Q-type calcium channels by ethanol in PC12 cells. *J Pharmacol Exp Ther* 282: 1487–1495.
- Solomon GD, Steel JG, Spaccavento LJ (1983). Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. *JAMA* 250: 2500–2502.
- Soong TW, DeMaria CD, Alvania RS, Zweifel LS, Liang MC, Mittman S *et al.* (2002). Systematic identification of splice variants in human P/Q-type channel alpha1(2.1) subunits: implications for current density and Ca²⁺-dependent inactivation. *J Neurosci* 22: 10142–10152.
- Stea A, Tomlinson WJ, Soong TW, Bourinet E, Dubel SJ, Vincent SR *et al.* (1994). Localization and functional properties of a rat brain alpha 1A calcium channel reflect similarities to neuronal Q- and P-type channels. *Proc Natl Acad Sci U S A* 91: 10576–10580.
- Stefani A, Pisani A, De Murtas M, Mercuri NB, Marciani MG, Calabresi P (1995). Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. *Epilepsia* 36: 997–1002.
- Stefani A, Spadoni F, Siniscalchi A, Bernardi G (1996a). Lamotrigine inhibits Ca²⁺ currents in cortical neurons: functional implications. *Eur J Pharmacol* 307: 113–116.
- Stefani A, Calabresi P, Pisani A, Mercuri NB, Siniscalchi A, Bernardi G (1996b). Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. *J Pharmacol Exp Ther* 277: 121–127.
- Stefani A, Spadoni F, Bernardi G (1997). Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. *Exp Neurol* 147: 115–122.
- Stotz SC, Spaetgens RL, Zamponi GW (2000). Block of voltage-dependent calcium channel by the green mamba toxin calcicludine. *J Membr Biol* 174: 157–165.
- Striano P, Striano S (2008). Gabapentin: a Ca²⁺ channel alpha 2-delta ligand far beyond epilepsy therapy. *Drugs Today* 44: 353–368.
- Study RE (1994). Isoflurane inhibits multiple voltage-gated calcium currents in hippocampal pyramidal neurons. *Anesthesiology* 81: 104–116.

- Suman-Chauhan N, Webdale L, Hill DR, Woodruff GN (1993). Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies. *Eur J Pharmacol* 244: 293–301.
- Sutton KG, Siok C, Stea A, Zamponi GW, Heck SD, Volkmann RA *et al.* (1998). Inhibition of neuronal calcium channels by a novel peptide spider toxin, DW13.3. *Mol Pharmacol* 54: 407–418.
- Sutton KG, Martin DJ, Pinnock RD, Lee K, Scott RH (2002). Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. *Br J Pharmacol* 135: 257–265.
- Takeuchi K, Park E, Lee C, Kim J, Takahashi H, Swartz K *et al.* (2002). Solution structure of omega-grammotoxin SIA, a gating modifier of P/Q and N-type Ca(2+) channel. *J Mol Biol* 321: 517–526.
- Terlau H, Olivera BM (2004). Conus venoms: a rich source of novel ion channel-targeted peptides. *Physiol Rev* 84: 41–68.
- Tollefson GD (1990). Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. *Biol Psychiatry* 27: 1133–1142.
- Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F (2008). Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. *Clin Exp Hypertens* 30: 744–766.
- Tottene A, Conti R, Fabbro A, Vecchia D, Shapovalova M, Santello M *et al.* (2009). Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine mice. *Neuron* 61: 762–773.
- Tottene A, Urbani A, Pietrobon D (2011). Role of different voltage-gated Ca²⁺ channels in cortical spreading depression: specific requirement of P/Q-type Ca²⁺ channels. *Channels (Austin)* 5: 110–114.
- Trepakova ES, Dech SJ, Salata JJ (2006). Flunarizine is a highly potent inhibitor of cardiac hERG potassium current. *J Cardiovasc Pharmacol* 47: 211–220.
- Viana F, Van den Bosch L, Missiaen L, Vandenberghe W, Droogmans G, Nilius B *et al.* (1997). Mibefradil (Ro 40-5967) blocks multiple types of voltage-gated calcium channels in cultured rat spinal motoneurons. *Cell Calcium* 22: 299–311.
- Vieira LB, Kushmerick C, Hildebrand ME, Garcia E, Stea A, Cordeiro MN *et al.* (2005). Inhibition of high voltage-activated calcium channels by spider toxin PnTx3-6. *J Pharmacol Exp Ther* 314: 1370–1377.
- Vohora D, Saraogi P, Yazdani MA, Bhowmik M, Khanam R, Pillai KK (2010). Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. *Drugs Today (Barc)* 46: 265–277.
- Wauquier A, Ashton D, Marrannes R (1985). The effects of flunarizine in experimental models related to the pathogenesis of migraine. *Cephalalgia* 5 (Suppl. 2): 119–123.
- Webster LR, Fisher R, Charapata S, Wallace MS (2009). Long-term intrathecal ziconotide for chronic pain: an open-label study. *J Pain Symptom Manage* 37: 363–372.
- Wermeling DP (2005). Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. *Pharmacotherapy* 25: 1084–1094.
- Winterfield JR, Swartz KJ (2000). A hot spot for the interaction of gating modifier toxins with voltage-dependent ion channels. *J Gen Physiol* 116: 637–644.
- Wu LG, Saggau P (1995). Block of multiple presynaptic calcium channel types by omega-conotoxin-MVIIC at hippocampal CA3 to CA1 synapses. *J Neurophysiol* 73: 1965–1972.
- Yakash TL (2006). Calcium channels as therapeutic targets in neuropathic pain. *J Pain* 7: S13–S30.
- Yamamoto T, Takahara A (2009). Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. *Curr Top Med Chem* 9: 377–395.
- Yan L, Adams ME (2000). The spider toxin omega-Aga IIIA defines a high affinity site on neuronal high voltage-activated calcium channels. *J Biol Chem* 275: 21309–21316.
- Yan Z, Chi P, Bibb JA, Ryan TA, Greengard P (2002). Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. *J Physiol* 540: 761–770.
- Ye Q, Yan LY, Xue LJ, Wang Q, Zhou ZK, Xiao H *et al.* (2011). Flunarizine blocks voltage-gated Na(+) and Ca(2+) currents in cultured rat cortical neurons: a possible locus of action in the prevention of migraine. *Neurosci Lett* 487: 394–399.
- Yu W, Horowitz SH (2003). Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. *Neurology* 60: 120–121.
- Zamponi GW, Lory P, Perez-Reyes E (2010). Role of voltage-gated calcium channels in epilepsy. *Pflugers Arch* 460: 395–403.
- Zhu G, Okada M, Murakami T, Kawata Y, Kamata A, Kaneko S (2002). Interaction between carbamazepine, zonisamide and voltage-sensitive Ca²⁺ channel on acetylcholine release in rat frontal cortex. *Epilepsy Res* 49: 49–60.
- Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C *et al.* (1997). Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. *Nat Genet* 15: 62–69.